Document Name: GCT1015- 04 Redacted Protocol and Summary of Protocol Amendments  Genmab  
 
Confidential  1 PROTOCOL AND SUMMARY OF PROTOCOL 
AMENDMENTS  
A Single arm, Multicenter, International Trial of Tisotumab 
Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent 
or Metastatic Cervical Cancer  
Protocol no.: GCT1015-04 
Trial name innovaTV 204 
ClinicalTrials.gov Identifier  [STUDY_ID_REMOVED]  
Sponsor:  Genmab A/S  
Collaborators : Seattle Genetics , Inc. 
EudraCT No.: 2017-003413-25 
IND No.:  135476 
IMP Name : Tisotumab vedotin (HuMax®-TF-ADC)  
Development Phase : 2 
 
   
 
*Genmab is a global organization that operates through different legal entities in various countries. 
Therefore, the legal entity acting as the sponsor for Genmab trials may vary, such as, but not limited to 
Genmab Holding B.V.; Genmab A/S; or Genmab US, Inc. The term “sponsor” is used throughout the 
protocol to represent these various legal entities; the sponsor is identified on the following sponsor 
information page.  
The information in this document is confidential and is propri etary to Genmab. It is understood that information in this 
document shall not be disclosed to any third party, in any form, without prior written consent of an authorized officer of 
Genmab  
Document Name: GCT1015- 04 Redacted Protocol and Summary of Protocol Amendments  Genmab  
 
Confidential  2 TABLE OF CONTENTS  
TABLE OF CONTENTS  .................................................................................................. 2  
1 OVERVIEW OF PROTOCOL  AMENDMENTS  .................................................. 3  
2 SUMMARY OF PROTOCOL AMENDMENTS  .................................................... 4  
3 REDACTED PROTOCOL VE RSION 7.0, LATEST VE RSION  ......................... 7  
 
  
Document Name: GCT1015- 04 Redacted Protocol and Summary of Protocol Amendments  Genmab  
 
Confidential  3 1 OVERVIEW OF PROTOCOL AMENDMENTS  
 
Protocol/Amendment No; Version  Issue Date  
Version 1.0  (never submitted externally)  03 November 2017 
Version 2.0  (original protocol)  09 November 2017  
Amendment 1; Version  3.0 22 January 2018  
Amendment 2; Version 4.0 09 February 2018  
Amendment 3; Version 5.0 12 February 2018  
Amendment 4; Version 6.0 01 November 2018  
Amendment 5; Version 7.0 17 June 2019  
 
  
Document Name: GCT1015- 04 Redacted Protocol and Summary of Protocol Amendments  Genmab  
 
Confidential  4 2 SUMMARY OF PROTOCOL AMENDMENTS  
Five protocol amendments have been  made to the original protocol (dated 09- Nov-2017, protocol 
version 2. Note that version 1 was never submitted externally to investigators, health  authorities, 
IRBs or IEC s), of which the first 3  were issued before the first  subject ’s first visit. A summary of 
key changes with each amendment is provided in Table 1 . 
Table 16.1.1-1 Protocol Amendments  
Amendment 
Number  Issue Date  Key Changes  
1 22-Jan-2018  
(protocol 
version 3)  The voluntary harmonisation procedure (VHP) for a coordinated European 
assessment resulted in recommendations and requests for changes to the protocol.  
• Justification for having no control group was added.  
• Based on the information on contraindications, potential risks, and identified 
risks in the current version of the investigator’s brochure, subjects with ongoing acute or chronic inflammatory skin disease, subjects with inflammatory lung 
disease, and subjects with inflammatory bowel disease were to be excluded from participation in the trial.  
• A subgroup analysis by region (EU/US) was added to assess regional consistency 
of treatm ent effects.  
• The term “analysis cut -off date” was defined for clarity.  
• In addition to the 2 already defined treatment periods (pretreatment and on-treatment periods) a third post- treatment observation period was defined.  
• The assumption of the 25% true OR R was justified.  
2 09-Feb-2018  
(protocol 
version 4)  After reviewing amendment 1, the VHP requested that the protocol be amended to 
clarify the statistical power for ORRs in the range 21 -25%.  
Document Name: GCT1015- 04 Redacted Protocol and Summary of Protocol Amendments  Genmab  
 
Confidential  5 Amendment 
Number  Issue Date  Key Changes  
3 12-Feb-2018  
(protocol 
version 5)  • It was specified when the imaging assessments should start and stop. In addition, 
the frequency of survival follow -up was specified.  
• It was specified that chemotherapy administered in the adjuvant or neoadjuvant 
setting, or in combination with radiation t herapy, should not be counted as a prior 
systemic treatment regimen.  
• Wording of “acceptable coagulation status” was clarified for subjects on anti-coagulation therapy and for subjects not on anti -coagulation therapy.  
• The ophthalmological exclusion criterion was revised for clarity.  
• The corticoid exclusion criterion was reworded and inserted as exclusion criterion 12.  
• It was clarified that if a subject intends to conceive children, she is ineligible for trial participation.  
• The time frame for prophylactic use of preservative -free lubricating eye drops 
was specified.  
• Guidance on permitted concomitant anti -coagulation therapy was revised for 
clarity.  
• The dose reduction scheme and dose delay rules were revised.  
• The plan for mitigating ocular AEs was revised du e to  requirements 
including the following:  
• It was specified that in case of second occurrence of grade 2 conjunctivitis, the dosing of tisotumab vedotin was to be held and be resumed at a reduced dose if the event resolved to baseline within 6  weeks. I f the event did not 
resolve to baseline within 6 weeks, treatment with tisotumab vedotin was to be permanently discontinued.  
• It was specified that treatment with tisotumab vedotin was to be permanen
tly discontinued if a subject experiences a third occurrence of 
grade 2 conjunctivitis or any occurrence of grade ≥3 conjunctivitis.  
• It was spe
cified that in case of a grade 1 keratitis, the dosing of tisotumab 
vedotin was to be held until the event was managed effectively, after which treatment could continue on the same dose.  
• A mitigation plan was added in order to include guidance on how to handle all other ocular AEs as well.  
• The mitigation plan for bleeding events was modified to specify that any event of 
pulmonary or CNS hemorrhage, irrespective of the grade, would lead to permanent discontinuation of treatment.  
• The withdrawal criterion “sponsor decision in consultation with the investigator” was deleted as this is an investigator decision.  
• It was specified that the AE reporting period ends 30 days after las t dose, that no 
new AEs should be collected after this period, and that for subjects who start any new anti -cancer therapy during the AE reporting period, only AEs that are 
related to tisotumab vedotin should be reported.  
• Due to  requirements, it was  specified that all ocular AEs, independent of 
grading, should be reported to the safety CRO within 24 hours.  

Document Name: GCT1015- 04 Redacted Protocol and Summary of Protocol Amendments  Genmab  
 
Confidential  6 Amendment 
Number  Issue Date  Key Changes  
4 01-Nov-2018  
(protocol 
version 6)  The main reasons for updating the protocol were:  
• To expand the time window for screening visit 2 by 2 days, so that this visit now could be performed ≤7 days prior to Cycle 1 (D1) (instead of ≤5 days prior to 
Cycle 1 [D1]).  
• To clarify that tisotumab vedotin was to be administered over a minimum of 
30 minutes and preferably be completed within 60 minutes.  
• To clarify the requirements for body weight measurement for dose calculation.  
• To align safety reporting requirements across the tisotumab vedotin program.  
 
5 17-Jun-2019  
(protocol 
version 7)  Based on health authority feedback, the timing of the primary analysis of the trial 
was changed to ensure that all responders were followed for ≥ 6 months.  
 
  
Document Name: GCT1015- 04 Redacted Protocol and Summary of Protocol Amendments  Genmab  
 
Confidential  7 3 REDACTED PROTOCOL VE RSION 7.0, LATEST VERSION  
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  2 TABLE OF CONTENTS  
STATEMENT OF COMPLIA NCE  ................................ ................................ ............................  6 
ABBREVIATIONS  ................................ ................................ ................................ .......................  7 
PROTOCOL AMENDMENTS  ................................ ................................ ................................ .... 9 
TRIAL SYNOPSIS  ................................ ................................ ................................ ......................  11 
1 VISIT ASSESSMENT SCH EDULE  ................................ ................................ .. 17 
2 INTR ODUCTION  ................................ ................................ ...............................  21 
2.1 Background  ................................ ................................ ................................ ............  21 
2.1.1  Overview of Disease  ................................ ................................ ..............................  21 
2.1.2  Introduction to the Investigational Medicinal Product  ................................ ..........  21 
2.1.3  Summary of Non -clinical Studies  ................................ ................................ ..........  21 
2.1.4  Summary of Clinical Trials  ................................ ................................ ...................  22 
2.2 Rationale  ................................ ................................ ................................ ................  24 
2.3 Benefit -risk Ass essment  ................................ ................................ ........................  25 
3 OBJECTIVES AND ENDPO INTS  ................................ ................................ .... 26 
4 TRIAL DESIGN  ................................ ................................ ................................ .. 27 
4.1 Description of  Trial Design  ................................ ................................ ...................  27 
4.2 Trial Design Rationale  ................................ ................................ ...........................  27 
4.3 Dose and Schedule Rationale  ................................ ................................ ................  28 
4.4 End of Trial and Treatment Discontinuation Definitions  ................................ ...... 28 
4.4.1  End of Trial  ................................ ................................ ................................ ............  28 
4.4.2  Treatment Discontinuation  ................................ ................................ ....................  28 
4.4.3 Trial Termination  ................................ ................................ ................................ ... 28 
5 TRIAL POPULATION  ................................ ................................ .......................  29 
5.1 Inclusion Criteria  ................................ ................................ ................................ ... 29 
5.2 Exclus ion Criteria  ................................ ................................ ................................ .. 30 
5.3 Screen Failures ................................ ................................ ................................ ....... 32 
6 TREATMENT  ................................ ................................ ................................ ..... 33 
6.1 Treatment Assignment  ................................ ................................ ...........................  33 
6.1.1  Patient Numbering  ................................ ................................ ................................ . 33 
6.1.2  Treatment Assignment  ................................ ................................ ...........................  33 
6.2 Dosage and Administration  ................................ ................................ ...................  33 
6.2.1  IMP ................................ ................................ ................................ ........................  33 
6.2.2  Pre-medication  ................................ ................................ ................................ ....... 33 
6.2.3  Suppor tive Care  ................................ ................................ ................................ ..... 34 
6.3 Compliance  ................................ ................................ ................................ ............  34 
6.4 Concomitant Medications and Therapies  ................................ ..............................  34 
6.4.1  Permitted Concomitant Medications and Therapies  ................................ ..............  34 
6.4.2  Permitted Concomitant Therapy Requiring Caution and/or Action  ......................  34 
6.4.3  Prohibited Concomitant Therapy  ................................ ................................ ...........  35 
6.5 IMP Information  ................................ ................................ ................................ .... 35 
6.5.1  Physical  Description of the IMP  ................................ ................................ ............  35 
6.5.2  Packaging  ................................ ................................ ................................ ...............  35 
6.5.3  Labeling  ................................ ................................ ................................ .................  35 
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  3 6.5.4  Preparation, Handling and Storage  ................................ ................................ ........  35 
6.5.5  Drug Accountability  ................................ ................................ ..............................  36 
6.5.6  Handling of Other Trial Treatment  ................................ ................................ ........  36 
6.6 Technical Complaint Handling  ................................ ................................ ..............  36 
6.6.1  Procedures  ................................ ................................ ................................ .............  36 
6.6.2  Contacting Sponsor Regarding Product Quality  ................................ ...................  36 
7 DOSE MODIFICATIONS A ND SAFETY MANAGEMENT  
GUIDELINES  ................................ ................................ ................................ ...... 37 
7.1 Dose Modification Guidance  ................................ ................................ .................  37 
7.1.1  Dose Reduction  ................................ ................................ ................................ ...... 37 
7.1.2  Dose delay  ................................ ................................ ................................ .............  37 
7.2 Mitigation Plans for Specific Adverse Events  ................................ .......................  38 
7.2.1  Ocular Adverse Events  ................................ ................................ ..........................  38 
7.2.2  Other Adverse Events  ................................ ................................ ............................  41 
7.3 Summary of Safety Stopping Rules  ................................ ................................ ....... 43 
8 DISCONTINUATION, FOL LOW -UP AND COMPLETIO N .......................  45 
8.1 Discontinuation of Treatment  ................................ ................................ ................  45 
8.2 Withdrawal from the Trial  ................................ ................................ .....................  45 
8.3 Withdrawal from the Optional Research Samples ................................ .................  46 
8.4 Withdrawal from the Use of Samples in Future Research  ................................ .... 46 
8.5 Follow -up for Safety Evaluations  ................................ ................................ ..........  46 
8.6 Lost to Follow -up ................................ ................................ ................................ .. 46 
9 TRIAL ASSESSMENTS  ................................ ................................ .....................  47 
9.1 Demography and Baseline Assessments  ................................ ...............................  47 
9.1.1  Demographics  ................................ ................................ ................................ ........  47 
9.1.2  Medical History  ................................ ................................ ................................ ..... 47 
9.1.3  Concomitant Medication  ................................ ................................ .......................  47 
9.1.4  Prior Cancer Therapy and Surgery  ................................ ................................ ........  47 
9.2 Efficacy assessments  ................................ ................................ .............................  47 
9.2.1  Tumor imaging:  ................................ ................................ ................................ ..... 47 
9.2.2  Survival Status  ................................ ................................ ................................ ....... 50 
9.3 Clinical Safety Assessments  ................................ ................................ ..................  50 
9.3.1  Physical Examination  ................................ ................................ ............................  50 
9.3.2  Body Measurements  ................................ ................................ ..............................  50 
9.3.3  Vital Signs  ................................ ................................ ................................ .............  50 
9.3.4  Electrocardiograms  ................................ ................................ ................................  51 
9.3.5  ECOG  ................................ ................................ ................................ ....................  51 
9.3.6  Eye Examination and Ophthalmological Evaluation  ................................ .............  51 
9.4 Pharmacokinetics  ................................ ................................ ................................ ... 52 
9.4.1  Evaluations  ................................ ................................ ................................ ............  52 
9.4.2  Analytical Procedures  ................................ ................................ ............................  52 
9.5 Clinical Laboratory Assessments  ................................ ................................ ..........  52 
9.6 Immunogenicity  ................................ ................................ ................................ ..... 54 
9.6.1  Evaluations  ................................ ................................ ................................ ............  54 
9.6.2  Immunogeni city Assessments  ................................ ................................ ...............  54 
9.7 Biomarker Investigations  ................................ ................................ .......................  54 
9.7.1  Biomarker Assessments in Tumor Samples  ................................ ..........................  54 
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  4 9.7.2  Biomarker Assessments in Blood Samples  ................................ ...........................  55 
9.7.3  Sample collections  ................................ ................................ ................................ . 56 
9.7.4  Additional Analyses  ................................ ................................ ..............................  56 
9.8 Pharmacogenomic (DNA) Evaluations  ................................ ................................ . 56 
9.9 Patient Reported Outcomes  ................................ ................................ ...................  57 
10 SAFETY MONITORING AN D ADVERSE EVENT REPO RTING  .............  58 
10.1  Adverse Event Definitions  ................................ ................................ .....................  58 
10.1.1  Definition of Adverse Events  ................................ ................................ ................  58 
10.1.2  Definition of  Serious Adverse Events  ................................ ................................ ... 58 
10.1.3  Definition of Adverse Events of Special Interest  ................................ ..................  58 
10.1.4  Definition of Overdose of Tisotumab Vedotin  ................................ ......................  59 
10.1.5 Definition of Reproductive Potential and Contraception  ................................ ...... 59 
10.1.6  Definition of Infusion Related Reactions  ................................ ..............................  60 
10.2  Reporting  ................................ ................................ ................................ ...............  60 
10.2.1  Pre-existing Conditions  ................................ ................................ .........................  62 
10.2.2  Diagnosis  ................................ ................................ ................................ ...............  62 
10.2.3  Disease Progression or Death  ................................ ................................ ................  62 
10.2.4  Unrelated Procedures  ................................ ................................ .............................  62 
10.2.5  Laboratory test abnormalities  ................................ ................................ ................  62 
10.2.6  Start Date and Time  ................................ ................................ ...............................  63 
10.2.7  Infusion -Related Reactions (IRRs)  ................................ ................................ ........  63 
10.2.8  Seriousness Criteria  ................................ ................................ ...............................  63 
10.2.9  Intensity  ................................ ................................ ................................ .................  63 
10.2.10  Relationship to the Investigational Medicinal Product  ................................ ..........  63 
10.2.11  Action Taken with the Investigational Medicinal Product  ................................ .... 63 
10.2.12  Outcome  ................................ ................................ ................................ .................  64 
10.2.13  End Date and Time  ................................ ................................ ................................  64 
10.3  Events Requiring Immediate Reporting  ................................ ................................  64 
10.3.1  Serious Adverse Events and Ocular Adverse Events  ................................ ............  64 
10.3.2  Overdose and Medication Errors  ................................ ................................ ...........  64 
10.3.3  Pregnancy  ................................ ................................ ................................ ..............  65 
10.4  Suspected Unexpected Serious Adverse Reactions (SUSARs)  .............................  65 
10.5  Follow -Up on Adverse Events ................................ ................................ ...............  65 
10.6  Warnings and Precautions  ................................ ................................ .....................  66 
10.7  Data Monitoring Committee  ................................ ................................ ..................  66 
11 STATISTICS  ................................ ................................ ................................ ........  67 
11.1  Analysis Sets  ................................ ................................ ................................ ..........  67 
11.1.1  Full An alysis Set  ................................ ................................ ................................ .... 67 
11.1.2  Safety Set  ................................ ................................ ................................ ...............  67 
11.2  Patient Demographics and Baseline Characteristics ................................ ..............  67 
11.3  Treatments  ................................ ................................ ................................ .............  67 
11.4  Primary Objec tive ................................ ................................ ................................ .. 67 
11.4.1  Endpoint  ................................ ................................ ................................ .................  68 
11.4.2  Statistical Hypothesis, Model and Method of Analysis  ................................ ........  68 
11.4.3  Handling of Missing Values/Censor ing/Discontinuations  ................................ .... 68 
11.4.4  Supportive and Sensitivity Analyses  ................................ ................................ ..... 68 
11.5  Secondary Objectives  ................................ ................................ ............................  68 
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  5 11.5.1  Secondary Efficacy Objectives  ................................ ................................ ..............  68 
11.5.2  Safety Objectives  ................................ ................................ ................................ ... 70 
11.5.3  Pharmacokinetics  ................................ ................................ ................................ ... 72 
11.5.4  Biomarkers  ................................ ................................ ................................ .............  72 
11.5.5  Resource Utilization  ................................ ................................ ..............................  73 
11.5.6  Patient -reported Outcomes  ................................ ................................ ....................  73 
11.6  Exploratory Objectives  ................................ ................................ ..........................  73 
11.7  Interim Analyses  ................................ ................................ ................................ .... 73 
11.8  Sample Size Calculation  ................................ ................................ ........................  73 
12 DATA HANDLING AND RE CORD KEEPING  ................................ .............  74 
12.1  Data Flow ................................ ................................ ................................ ...............  74 
12.2  Source Documentation ................................ ................................ ...........................  74 
12.3  Case Report Form Completion  ................................ ................................ ..............  75 
12.4  Data Quality Management  ................................ ................................ .....................  75 
12.5  Record Retention  ................................ ................................ ................................ ... 76 
13 ETHICS  ................................ ................................ ................................ ................  77 
13.1  Trial -Specific Design Considerations  ................................ ................................ .... 77 
13.2  Regulatory Ethics Compliance  ................................ ................................ ..............  77 
13.2.1  Investigator Responsibilities  ................................ ................................ ..................  77 
13.2.2  Independent Ethics Committee or Institutional Review Board  .............................  77 
13.2.3  Informed Consent  ................................ ................................ ................................ .. 77 
13.2.4  Privacy of Personal Data  ................................ ................................ .......................  78 
13.2.5  Long -term Retention of Samples  ................................ ................................ ...........  79 
14 ADMINISTRATIVE PROCE DURES  ................................ ...............................  80 
14.1  Protocol Amendments  ................................ ................................ ...........................  80 
14.2  Regulatory Documentation  ................................ ................................ ....................  80 
14.2.1  Regulatory Approval/Notification  ................................ ................................ .........  80 
14.3  Patient Identification, Enrollment, and Screening Logs  ................................ ........  80 
14.4  Monitoring  ................................ ................................ ................................ .............  80 
14.5  On-Site Audits  ................................ ................................ ................................ ....... 81 
14.6  Publication  ................................ ................................ ................................ .............  81 
15 REFERENCES  ................................ ................................ ................................ .... 83 
 
Appendix 1  Recommendations Related to Contraception and Pregnancy Testing in Clinical 
Trials  
Appendix 2  Investigator ’s Agreement  
Appendix 3  Signature from sponsor's responsible Medical Officer  
       
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  6 STATEMENT OF COMPLIA NCE  
GCP Compliance:  This trial will be conducted in compliance with International Conference on 
Harmonization  Good Clinical Practice  (ICH GCP  E6 [R2] ), and applicable regulatory 
requirements.  
Confidentiality Statement  
The information in this document contains trade secrets and commercial information that are 
privileged or confidential and may not be disclosed unless such disclosure is required  by applicable 
law or regulations. In any event, persons to whom the information is disclosed must be informed 
that the information is privileged or confidential and may not be further disclosed by them. These 
restrictions on disclosure will apply equally to all future information supplied to you that is 
indicated as privileged or confidential.  
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  7 ABBREVIATIONS  
 
1L First line  
2L Second line  
1Q3W  Once every 3 weeks  
3Q4W  Once weekly for 3 weeks followed by one week with no treatment  
ADA  Anti-drug antibody  
ADC  Antibody -drug conjugate  
AE Adverse event  
AESI  Adverse event  of special i nterest  
ALT  Alanine aminotransferase  
ANC  Absolute neutrophil count  
aPTT  Activated partial t hromboplastin time  
ASA  Acetyl salicylic a cid 
AST  Aspartate aminotransferase  
ATC  Anatomical therapeutic chemical  
AUC 0-t Area-under -the-concentration -time curve  
CI Confidence interval  
Cmax Maximum observed concentration  
CONSORT  Consolidated standards of reporting trials  
CR Complete response  
CXR  Chest X -ray 
eCRF  Electronic case report form  
CRO  Contract research organization  
CTCAE  Common terminology criteria for adverse events  
DOR  Duration of response  
ECG  Electrocardiogram  
ECOG  Eastern cooperative  oncology group 
EORTC -QLQ -C30 European organization for research and treatment  of cancer quality of 
life version 3.0 of the core questionnaire  
EORTC -QLQ -CX24  European organization for research and treatment of cancer quality  of 
life questionnaire , cervical cancer module  
FAS Full analysis set  
GCP  Good clinical practice  
GFR  Glomerular filtration rate 
HIV Human immunodeficiency virus  
HRQL  Health related quality of life 
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  8 ICF Informed consent form  
ICH International conference on harmonization  
IEC Independent ethics committee  
IMP Investigational medicinal product  
INR International normalized ratio  
IRB Institutional review board 
IRC Independent review committee  
ITT Intention to treat 
IV Intravenous  
MedDRA  Medical Dictionary for Regulatory Activities  
MMAE  Monomethyl auristatin E  
ORR  Objective response rate  
OS Overall survival  
PFS Progression free survival  
PK Pharmacokinetics  
PR Partial response  
PT Prothrombin time  
RECIST  Response evaluation criteria in solid tumors  
Q6W  Every 6 weeks  
Q12W  Every 12 weeks  
SAE  Serious adverse event  
SAP Statistical analysis  plan 
SD Standard deviation  
SUSAR  Suspected unexpected serious  adverse reactions  
TF Tissue factor  
TTR  Time to response  
ULN  Upper limit of normal  
  
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  13 - Paclitaxel +cisplatin or carboplatin   
       OR 
- Paclitaxel +topotecan,  
in combination with bevacizumab unless patients  are ineligible for 
bevacizumab  treatment according to local standards . 
o Have received no more than 2 prior systemic treatment 
regimens for recurrent or metastatic cervical cancer.  
Chemotherapy administered in the adjuvant or neoadjuvant 
setting, or in combination with radiation therapy should  not be 
counted as a prior systemic treatment regimen .  
o Are not candidates for curative therapy, including but not 
limited to, radiotherapy or exenterative surgery.  
 Measurable disease according to RECIST v1.1 as assessed by 
IRC.  
 Age ≥ 18 years.  
 Acceptable  renal function: Calculated (Cockcroft -Gault)  
Glomerular Filtration Rate (GFR)  > 50 mL/min.  
 Acceptable liver function: Alanine aminotransferase (ALT) and 
aspartate aminotransferase (AST) ≤  3 times the upper limit of 
normal (ULN) (if liver tumor/metastases are present, then ≤  5  
ULN is allowed); bilirubin ≤  1.5  ULN, except in patient s 
diagnosed  with Gilbert’s syndrome, direct bilirubin ≤  2  ULN.  
 Acceptable hematological status: Hemoglobin ≥  5.6 mmol/L 
(9.0 g/dL), absolute neutrophil count (ANC) ≥  1500/µL 
(1.5109/L); platelet count ≥  100109/L assessed at least 2 weeks 
after transfusion with bl ood products and/or growth factor 
support . 
 Acceptable coagulation status:  
o For patients not on anti -coagulation therapy : 
- Activated partial thromboplastin time (aPTT) ≤  1.25 ULN.  
- International  normalized ratio (INR) ≤  1.2. 
o For patients on anti -coagulation therapy:  
- aPTT ≤  1.25 ULN . 
- INR:  Patients on anti -coagula nts that requir e laboratory 
assessments for dose titration (warfarin  or other Vitamin K 
dependent anti -coagulant agents ) must be on a steady dose 
(no active titration) for ≥ 4 weeks prior to first plan ned 
administration  of tisotumab vedotin  and must have an INR 
≤ 2.5 for eligibility.  
- Patients on anti -coagulants that do not require laboratory 
assessments for dose titration do not need to be on a steady  
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  14 dose for ≥  4 weeks prior to first planned administration  of 
tisotumab vedotin .  
- Concurrent chronic use of prophylactic AcetylSalicylic 
Acid (ASA, e.g., aspirin) is prohibited for patients on any 
type of anti -coagulation therapy.  
 Eastern Cooperative  Oncology Gro up (ECOG) performance 
status of 0 or 1 prior to the first planned administration of IMP .  
 Life expectancy of at least three months.  
 A negative serum pregnancy test for patients of reproductive 
potential. Patients that are postmenopausal or permanently 
sterilized (please refer to Section 10.1.5  for definitions), can be 
considered as not having reproductive potential.  
 Patients of reproductive potential must agree to use adequate 
contr aception during and for 6 months after the last IMP 
administration. Adequate contraception is defined as highly 
effective methods of contraception (please refer to Section 10.1.5  
for more information). In countries where two highly effective 
methods of contraception are required this will be an inclusion 
criterion.  
 All p atients  must agree not to donate eggs  (ova, oocytes) for the 
purpose  of assisted reproduction during the trial and for 6 months 
after receiving the last dose of IMP. 
 All patients must provide a fresh or archival biopsy  prior to the 
first planned administration of IMP , unless determined it is 
unfeasible after sponsor medica l review . For specific tissue 
requirements, please refer to Section 9.7.3 .  
 Following receipt of verbal and written information about the trial, 
patients must provide signed informed consent before any trial -
related activity is carried out.  
Exclusion Criteria   Patients with primary neuroendocrine or sarcomatoid histologies.  
 Hematological: Known past or current coagulation defects leading 
to an increased risk of bleeding; diffuse alveolar hemorrhage from 
vasculitis; known bleeding diathesis; ongoing major bleeding; 
trauma with increased risk of life -threatening bleeding or his tory 
of severe head trauma or intracranial surgery within 8 weeks  of 
trial entry.  
 Cardiovascular: Clinically significant cardiac disease including 
unstable angina, acute myocardial infarction 6 months prior to 
screening; any medical history of  congestive h eart failure (Grade 
III or IV as classified by the New York Heart Association), any 
medical history of decreased cardiac ejection fraction of <  45%; a 
marked baseline prolongation of QT/QTc interval (e.g., repeated 
demonstration of a QTc interval >450 msec ); a complete left 
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  15 bundle branch block (defined as a QRS interval ≥  120 msec in left 
bundle branch block form) or an incomplete left bundle branch 
block.  
 Central nervous system: Any history of intracerebral 
arteriovenous malformation, cerebral aneurysm, or  stroke 
(transient ischemic attack >  1 month prior to screening is 
allowed).  
 Ophthalmological : Active ocular surface disease at baseline. 
Patients with any prior episode of cicatricial conjunctivitis or 
Steven Johnson syndrome are ineligible . 
 Other cancer: Known past or current malignancy other than 
inclusion diagnosis, except for: Non-invasive basal cell or 
squamous cell skin carcinoma; noninvasive, superficial bladder 
cancer; any curable cancer with a complete response (CR) of 
 5 years durat ion. 
o Brain metastases  are allowed  if the following criteria are met : 
Definitive therapy (for example: surgery or stereotactic brain 
radiotherapy) has been completed > 8 week s before the first 
dose of IMP; no evidence of clinical or radiologic progression  
of the brain metastases ; patients have completed perioperative 
corticosteroid therapy or steroid taper. NOTE: Chronic steroid 
therapy is acceptable provided that the dose is stable for 1 
month prior to screening.  
 Surgery/procedures: Major surgery within 4  weeks or minor 
surgery within 7 days prior to  the first IMP administration . 
Patient s who have planned major surgery during the treatment 
period must  be excluded from the trial.  
 Peripheral neuropathy grade > 2. 
 Prior therapy : 
o Any prior treatment with  MMAE -derived drugs . 
o Radiotherapy within 21 days prior to the first administration 
of IMP. Patients must have recovered from all clinically 
significant radiation -related toxicities. At least 42 days must 
have elapsed from the last administration of chemo -
radiotherapy.  
o Small molecules, chemotherapy, immunotherapy, monoclonal 
antibodies , or any experimental agents  (not specified in this 
protocol)  within 28 days  prior to the first administration of 
IMP. 
 Other: Ongoing significant, uncontrolled medical conditio n; 
clinically significant active viral, bacterial or fungal infection 
requiring IV or oral treatment with antimicrobial therapy ending 
less than 7 days prior to first IMP administration ; clinically 
relevant b ilateral hydronephrosis which cannot be alleviat ed by 
ureteral stents or percutaneous drainage ; patients with clinical 
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  16 symptoms or signs of gastrointestinal obstruction and who require 
parental hydration and/or nutrition; inflammatory bowel disease 
including Crohn's disease and colitis ulcerosa; ongoing  acute or 
chronic inflammatory skin disease; inflammatory lung disease 
including moderate and severe asthma and chronic obstructive 
pulmonary disease (COPD) requiring chronic medical therapy . 
 Known  seropositivity  of human immunodeficiency virus; known 
medi cal history or ongoing  hepatitis B or C infection . 
 Has a diagnosis of immunodeficiency or is receiving systemic 
steroid therapy (dosing exceeding 10 mg daily of prednisone or 
equivalent) or any other form of immunosuppressive therapy 
within 7 days prior to  the first dose of tisotumab vedotin.  
 Patient is p regnan t, breast feeding  or intends to conceive children 
starting from date of signed ICF and continuing until  6 months 
after the last dose of trial treatment.  
 Patient  has any condition for which, in the op inion of the 
investigator, participation would not be in the best interest of the 
patient  (e.g. compromise the well -being) or that could prevent, 
limit, or confound the protocol -specified assessments.  
 Patient  has known allergies, hypersensitivity, or intolerance to 
tisotumab vedotin or its excipients  (please refer to the 
Investigator's Brochure) . 
Efficacy Assessments  To investigate the confirmed ORR of tisotumab vedotin per RECIST 
v1.1 assessed by IRC in patient s with previously treated, recurrent or 
metastatic  cervical cancer.  
Safety Assessments  To assess  the safety and tolerability of tisotumab vedotin.  
Other Assessments  Not applicable  
Statistics  The primary analysis of confirmed ORR and a 2 -sided 95%  exact 
confidence interval will be calculated based on a data cutoff 
approximately 6 months after all responders have experienced their 
first response as assessed by the investigator  per RECIST v1.1. 
Assuming a true confirmed ORR of 21% - 25% for tisotumab vedotin, 
100 patient s provides 80% power to exclude an ORR of 11% or less . 
GCP Compliance  This trial will be conducted in compliance with International 
Conference on Harmonisation Good Clinical Practice (ICH GCP  
[R2]), and applicable regulator y requirements.  
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  17 1 VISIT ASSESSMENT SCH EDULE  
Table 1-1 lists all of the assessments and indicates with an “X” the visits when they are performed. 
All data obtained from these assessments must be supported in the patient ’s source documentation. 
Table 1-2 shows the timing of the PK sampling . 
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  19  
Footnotes to Trial Flowchart  
1 Day 1 of cycle 1 is to be performed no more than 28 days after screening visit  1. Each cycle is 21 days. Day 1 of cycle 2 is to be performed 21 days ± 3 days after day 1 of cycle 1, day 1 of cycle 
3 is to be performed 21 days ± 3 days after day 1 of cycle 2 etc. 
2 Survival follow -up is to be performed  every 60 days (±7days) , beginning  from  the day  of last IMP dose , and include collection of  survival  status  and information of any  new anti -cancer treatment . 
3 The day 4 and day 8 visits are only to be performed for cycle 1. The d ay 8 visit should  be performed at least 72 hours after the day 4 visit.  
4 Informed consent can be obtained outside the screening visit window (but should be obtained within a reasonable window prior to the screening date).  
5 An unscheduled visit can be setup if deemed necessary.  Relevant assessments should be made depending on the reason for the unscheduled visit. 
6 All patients will have a chest X -ray (CXR), and CT or MRI scan of the abdomen and pelvis performed during screening. Please refer to  9.2.1.1 . 
7 CT or MRI scans  must be performed every 6 weeks (±7 days) for the first 30 weeks and every 12 weeks (±7 days) thereafter, calculated from the  date of first IMP dosing. Imaging should continue 
until the patient experiences IRC verified disease progression, begins a new an ti-cancer therapy, withdraws from the trial or dies, whichever comes first. Time points for radiographic evaluation 
should be calendar based and does not depend on cycle visits i.e. radiological evaluation should  be performed regardless of IMP administrati on delays . 
8 ECOG assessment and local laboratory values for biochemistry, hematology and coagulation factors must be obtained and reviewe d by the investigator within 24 hours prior to IMP administration 
from cycle 2 and onwards. ECOG assessment and local  laboratory values do not need to be obtained prior to first dosing of IMP (cycle 1, day 1). If ECOG is assessed and/or local laboratory values 
are obtained, after patient enrolment  has been granted and  prior  to first administration of IMP, these parameters  must meet eligibility criteria. If they do not, investigator must hold IMP dosing and 
contact the sponsor Medical Officer . 
9 Health related quality of life questionnaires should be completed by the patient as first thing upon arrival for a visit (i.e. before any disease or treatment -related dialog with the study nurse/treating 
physician or initiation of other preparations for the trial/IMP infusion). Health related quality of life questionnaires must  be completed at the screening visit, on d ay 1 of cycle 2 and 4 and at the 
treatment discontinuation visit.  
10 Please specifically ask if the patient has experienced any bleeding events, peripheral neuropathy and/or ocular adverse event s. 
11 To be p erformed by  the treating physician: Patients sh ould be questio ned about any changes in sight/ ocular symptoms . A visual inspection of the eye orbit and conjunctiva and control of normal 
eye movement  should be performed . All patients should be informed to contact their treating physician immediately in c ase of any ocular symptoms appearing between IMP administration days.  
12 The patient  should  be referred to an ophthalmologist for prompt review (preferably within 72 hours and no later than within one week) in case of  ocular symptoms any time during trial and/or any 
abnormal findings during the eye examination  performed by the treating physician .  
13 To be performed by an ophthalmologist: All patients must have their eyes evaluated by an ophthalmologist during screening . 
14 Preventive eye therapy must be administered prior to each IMP administration. Refer to Section 6.2.2 . 
15 Any change in the patient´s trial status should be recorded on the relevant forms in the eCRF .  
16 All laboratory parameters will be analyzed centrally, except coagulation parameters which must be measured locally.  
17 INR, aPTT and PT must be measured locally (i.e., no central measurements should be performed for these values). Please refer to Table 9-3. 
18 Only for patients of reproductive potential (please refer to Section 10.1.5  for definition). Serum (beta -hCG) laboratory test must be taken at screening (analyzed centrally). A urine pregnancy test 
(performed locally) must be taken every second cycle, i.e., on day 1 of cycles 1, 3, 5, etc., at the treatment discontinuatio n visit and at the safety follow -up visit. 
19 Sample to be taken before IMP administration.  
20 The most recent available archived sample should be used. If no biopsies are available, a new biopsy must be obtained before IMP administration, unless reviewed by sponsor ’s Medical Officer  
and deemed unfeasible.  
21 Optional tumor sample at time of IRC verified progressive disease.  
22 Sample to be taken before IMP administration, at cycles 1, 2, 3, 4 and 5  
23 Only at cycle 1.  
24 Sample to be taken before IMP administration, at cycles 1, 2, 4 and 8.  
25 Sample to be taken before IMP administration at cycle  1 
  
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  21 2 INTRODUCTION  
2.1 Background  
2.1.1 Overview of Disease  
Cervical cancer poses a significant medical problem worldwide with an estimated incidence of more 
than 500,000 new cases. The disease accounts for approximately 8% of female cancer deaths (Ferlay 
et al., 2012 ) and up to 85% of deaths in some developing countries. In the US, approximately 12,800 
new cases and 4,210 deaths are estimated to occur this year (American Cancer Society, 2017 ). 
2.1.2 Introduction to the I nvestigational Medicinal Product  
The investigational medicinal product (IMP), t isotumab vedotin , is an antibody -drug conjugate (ADC) 
composed of a human monoclonal immunoglobulin G1 (subtype κ) targeting tissue factor (TF) 
conjugated via a protease cleavable valine citrulline linker to the drug monomethyl auristatin E  
(MMAE), a dolastatin 10 analog (Doronina et al., 2003; Hamblett et al., 2004; Sun et al., 2005 ). 
Dolastatins and auristatins belong to a class of chemotherapies that act as microtubule disrupting 
agents .  
Tisotumab vedotin efficiently binds to TF. TF has a central physiological role in initiation of the 
coagulation cascade but is during oncological transformation upregulated and expressed on the 
membrane of neoplastic cells as well as on tumor -associated en dothelial cells. Upon binding to TF, 
tisotumab vedotin is rapidly internalized into tumor cells where it undergoes lysosomal degradation 
resulting in release of the cytotoxic payload. Tumor cell death occurs due to MMAE -mediated 
disruption of microtubules and bystander “cytotoxicity” effect of neighboring tumor cells. Please refer 
to Section 2.2 for more details.  
2.1.3 Summary of Non-clinical Studies  
Tisotum ab vedotin treatment resulted in potent and long -lasting tumor regression in TF -expressing 
xenograft models derived from a variety  of solid cancers, including patient -derived xenograft models 
with heterogeneous TF expression . Moreover, potent tumor regress ion was observed in xenograft 
models of bladder, lung, cervical and ovarian cancer that had received prior treatment with paclitaxel.  
Given the contribution of TF in hemostasis, assessment of tisotumab vedotin in coagulation was 
performed. Tisotumab vedot in showed only modest impact (19% inhibition) on coagulation in an FXa 
generation assay and in thromboelastography studies. The effect of high dose treatment with the naked 
antibody, tisotumab, on coagulation parameters in vivo  was studied in cynomolgus mo nkeys. 
Tisotumab had no impact on coagulation parameters or functional bleeding time at a dose of 
100 mg/kg.  Furthermore, t isotumab vedotin had no impact on coagulation parameters at 5  mg/kg 
repeated dosing  in cynomolgus monkeys . 
The safety profile of tisotumab vedotin i n cynomolgus monkey studies  was as expected for 
MMAE/tubulin -disrupting agents.  
Further details on non-clinical studies can be found in the Investigator’s Brochure.  
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  22 2.1.4  Summary of Clinical Trials  
Tisotumab v edotin is being investigated in two clinical trials; GEN701 and GEN702 . Each trial 
consists of two parts;  I) a dose escalation part and II) a cohort expansion part. As of 16 -May-2018, 
238 patients have been enrolled across both trials . 
GEN701 : A first in human trial investigating treatme nt with tisotumab  vedotin once every 3 weeks 
(1Q3W) . The indications include d ovary, cervix, endometrium, bladder, castration -resistant prostate 
cancer, esophagus, non -small cell lung cancer , and squamous cell carcinoma of the head and neck . 
Part I) The dose escalation part has been fin alized. The recommended phase 2 dose was 
identified as  tisotumab vedotin 2.0 mg/kg 1Q3W.  
Part II) The expansion part of GEN701 is ongoing. Patients enrolled in the GEN701  expansion  
cohort s are administered  tisotumab vedotin  2.0 mg/kg  1Q3W.  
GEN702: Investigating  treatment with tisotumab  vedotin once weekly for 3 weeks followed by one 
week with no treatment (3Q4W).  The indications included o vary, cervix, endometrium, bladder, 
castration -resistant prostate cancer, esophagus an d non -small cell lung cancer . 
Part I) The dose escalation part has been finalized . The recommended phase 2 dose was 
identified as tisotumab vedotin 1.2 mg/kg  3Q4W.  
Part II) . Patients enrolled in the GEN702 expansion cohort were initially treated with the 
frequent dosing regimen of tisotumab vedotin 1.2 mg/kg 3Q4W . However, th is dosing regimen  
was later discontinued due to severe ocular adverse events (AEs)  and patients enrolled in 
GEN702 were instead  offered tisotumab vedotin  2.0 mg/kg 1Q3W, that in G EN701 had been 
found to be potentially efficacious and tolerable . GEN702 expansion part has been completed 
and CSR is pending.  
2.1.4.1  Summary of Clinical Sa fety across Indications  
As of 16-May-2018, 199 patients have received  tisotumab vedotin 1Q3W in doses rang ing from 0.3  to 
2.2 mg/kg . The number of patients by dose level was: 0.3 mg/kg (n=3); 0.6 mg/kg (n=3); 0.9  mg/kg 
(n=3); 1.2 mg/kg (n=3); 1.5 mg/kg (n=3); 1.8 mg/kg (n=3); 2.0 mg/kg (n=175); 2.2  mg/kg (n=6).  
Across all indications  enrolled on the 1Q3W dosin g regimen , the most commonly reported  treatment -
emergent AEs (hereafter referred to as AEs)  observed in > 20%  of the patients  were epistaxis (64%), 
fatigue (53%), nausea (47%), alopecia (4 0%), conjunctivitis ( 36%), constipation (3 4%), decreased 
appetite (3 3%), diarrhea (2 8%), vomiting (26%) and neuropathy peripheral (26%).  
Grade ≥ 3 AEs were reported in 5 7% of patients. The most frequently reported AEs ≥ grade 3 were 
fatigue ( 9.5%), anemia ( 7.0%), abdominal pain (4 .5%), hypokalemia (4 .0%), hyponatremia (3 .5%), 
vomiting ( 3.0%), dyspnea and conjunctivitis ( 2.5% each).  
Serious adverse events (SAEs) were reported in 47% of patients. Abdominal pain was the most 
frequently reported SAE (4 .5%), followed by vomiting  (3.0%), constipation, hyponatremia, and 
anemia  (2.5% each).  
AEs leading to discontinuation were reported in 30% of  patients; across all indications the most 
frequently AEs leading to discontinuation were neuropathy peripheral (5 .5%), conjunctivitis ( 3.5%), 
and peripheral sensory neuropathy ( 2.5%). 
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  23 Across all trials, eleven of 228 patients  (4.8%) experienced an AE with a fatal outcome.  Two patients  
died due to AEs considered by the investigator to be related to tisotumab vedotin (pharyngeal tumor 
hemorrhage [0.6 mg/kg 1Q3W] and pneumonia [2.0 mg/kg 1 Q3W]). The other fatal adverse events 
were not considered related to trial drug by the investigator and included disease progression (4 
patients ); general physical health deterioration (2 patients ); dyspnea (1 patient ); metastases to the 
central nervous sy stem (1 patient ) and oesophageal cancer metastatic (1 patient ). 
Safety data  from clinical trials with tisotumab vedotin  have demonstrated that tisotumab vedotin is 
tolerable . Furthermore, th e safety profile in the cervical cohort of GEN701 part II was comp arable to 
the profile observed for other indications.   
Three categories of Adverse Events of  Special Interest  (AESI)  have been identified  in relation to 
treatment with tisotumab vedotin : 
 Ocular AEs: AEs of grade 1 -2 conjunctivitis are frequently reported in relation to treatment 
with tisotumab vedotin. Severe cases (common terminology criteria for adverse events 
[CTCAE ]  grade 3) of conjunctivitis and keratitis have been observed, however 
implementation of a comprehe nsive mitigation plan and preventive measures (please refer to  
Section 7.2.1 ) have substantially reduced both the frequency and seve rity of conjunctival 
toxicity  in GEN701 part II.   
 AEs of p eripheral neuropathy  (including preferred terms as: neuropathy peripheral; peripheral 
sensory neuropathy; peripheral motor neuropathy; polyneuropathy): Peripheral neuropathy is 
a well -known adverse reaction to treatment with chemotherapeutics (including cisplatin and 
taxanes) as well as MMAE -based ADCs and is frequently reported in relation to treatment 
with tisotumab vedotin. The majority of the reported cases are grade 1-2; however peripheral 
neuro pathy was the leading cause of permanently discontinuation of IMP in GEN701  part II. 
A mitigation plan , including dose reduction and dose delay , is in place in order to prevent 
onset of peripheral neuropathy as well as deterioration of pre -existing conditi ons (please refer 
to Section 7.2.2 ). 
 AEs of bleeding:  Bleeding events are considered AESI due to the mode of action of IMP. In 
line with non-clinical findings, no major impact on activated partial thromboplastin time 
(aPTT) or  prothrombin time (PT) has until now been found for tisotumab vedotin treated 
patients . Epistaxis was the most common reported AE in GEN701 part II, however , nearly all 
of the cases were grade 1 . Excluding epistaxis, no causal relation to tisotumab vedotin  has 
been established for the majority of the reported bleeding events . One patient in the squamous 
cell carcinoma of the head and neck  indication  experienced an event of grade 5 pharyngeal 
hemor rhage in GEN701 part I (the event was evaluated as most likely due to the patient ’s 
baseline disease, however, a causal relationship to trial drug could at that point in time not 
completely be ruled out).  
For further details of adverse events  observed in relation to treatment with  tisotumab vedotin  please 
refer to Investigator ’s Brochure.  
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  24 2.1.4.2  Summary of Efficacy and Concentration Data  
Preliminary efficacy in GEN701 cervical cancer expansion cohort – first 34 patients:  
In GEN701 part II  (as of 16 -May-2018) , 11 patients (32%  [95% CI, 17 % to 51%] ) experienced a best 
overall response of partial response (PR), including 9 (26% [95% CI, 13% to 44%]) patients who had 
a confirmed response according to RECIST v1.1 based on investigator assessment . The median 
duration of response (DOR) in the co nfirmed responders was 5.5 months [95% CI, 3.0 months to 
9.6 months] . 
Concentration data:  
 
 
2.2 Rationale  
Tisotumab vedotin is an ADC targeting TF -expressing tumors through intracellular delivery of the 
potent and clinically validat ed agent MMAE. TF is expressed in a wide variety of tumors including 
the gynecological cancers of the ovary and cervix, genito -urethral tumors, squamous cell carcinoma 
of the head and neck, lung cancers, tumors in the gastrointestinal tract, breast cancer,  malignant 
melanoma and pancreatic cancer. TF is expressed on the membrane of neoplastic cells as well as on 
tumor -associated endothelial cells. Furthermore, expression of TF on tumor cells has been associated 
with negative overall survival or disease -free survival as described in several indications, including 
ovarian and bladder cancer.  
Tisotumab vedotin binds efficiently to human TF -expressing cells and is rapidly internalized into 
tumor cells where it undergoes lysosomal degradation resulting in release  of the cytotoxic payload.  
MMAE -mediated tumor cell killing is the dominant mechanism of action of tisotumab vedotin. Upon 
lysosomal degradation, tisotumab vedotin can induce bystander killing as a result of diffusion of free 
MMAE over the cell membrane, l eading to cytotoxicity against neighboring tumor cells.  In a bio -
distribution study in xenograft models, tisotumab vedotin effectively accumulated in TF -positive, but 
not TF -negative tumors.  
High, differential  levels of TF expression have been observed in multiple cancers including cervical 
cancer; as such  tisotumab vedotin is an attractive candidate as an anti -cancer therapy in cervical 
cancer.  
First-line (1L) treatment for recurrent or metastatic  cervical cancer is comprised  of bevacizumab 
combined with paclitaxel +platinum  (cisplatin or carboplatin) or paclitaxel +topotecan. Despite a 48% 
objective response rate (ORR) and a median overall survival (OS) of approximately 18  months, 
unfortunately almost all patients  relapse  after this 1L treatment  (Tewari et al., 2014 ). For second line 
(2L) therapy, no approved therapy is available and patients  are often treated with single agent 
modalities including, but not limited to : pemetrexed, topotecan, docetaxel, nab-paclita xel, vinorelbine 
and in some cases bevacizumab. A  meta -analysis of single agent treatment demonstrates a response 
rate o f 10.7% (95% CI: 8. 0%-13.3%) (57 responders out of 535 patient s) and median overall survivals 
(OS) of approximately  7 months  (Table 2-1). 

Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  25 Table 2-1 Reported Response Rates for Second -Line (2L) Treatment  
Drug(s)  Type of 
cervical 
cancer1 Trial 
phase  ORR2 median  
OS (months)  No. of  
evaluable  
patients  Reference  
Ixabepilone   2 10% 5.8 41 (Burotto et al., 2015)  
Imatinib  mesylate  SCC   0% 5 12 (Candelaria et al., 2009)  
Topotecan    0% 6.5 15 (2L) (Coronel et al., 2009)  
Topotecan   2 0% NA 25 (Fiorica et al., 2009)  
Docetaxel    9% 7.0 23 (Garcia et al., 2007)  
Gefitinib  SCC  2 0% 3 28 (Goncalves et al., 2008)  
Paclitaxel  SCC  2 10%  20 (Homesley et al., 2008)  
Systemic 2L therapy  in 
hospital    13% 9.3 53 (McLachlan et al., 2017)  
Pemetrexed   2 15% 7.4 27 (Miller et al., 2008)  
Bevacizumab  SCC  2 11% 7.3 46 (Monk et al., 2009)  
Vinorelbine  SCC  2 14% NA 44 (Muggia et al., 2004)  
Doxil  SCC  2 11% 8.9 26 (Rose et al., 2006)  
Cetuximab   2 0% 6.7 35 (Santin et al., 2011)  
Gemcitabine  Non SCC  2 5% 6.5 22 (Schilder et al., 2005)  
Paclitaxel3+Carboplatin    52% NA 23 (Torfs et al., 2012)  Paclitaxel4+Carboplatin  0% NA 13 
Pembrolizumab   2 13% NA 82 (Schellens et al., 2017)  
1: AC: adenocarcinoma; SCC: squamous cell carcinoma; 2: ORR: overall response rate; patients who receive a complete 
or partial response; 3:  dose dense; 4: weekly  
 
2.3 Benefit -risk Assessment  
Data from GEN701 part II demonstrate substantial efficacy of tisotumab vedotin in previously treated  
patients with recurrent or metastatic  cervical cancer along with a manageable safety profile. The safety 
profile of tisotumab vedot in in the cervical cohort was comparable to the profile observed for other 
indications.  
Given the lack of effective therapies for 2L+ patients , these preliminary safety and efficacy data 
suggest  a positive benefit -risk profile and warrant  further investig ation of tisotumab vedotin in a larger 
cohort of previously treated  patients with recurrent or metastatic  cervical cancer as a novel anti -cancer 
therapy for this population of high unmet need . 
Risks are addressed in Section  2.1.4.1 . 
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  27 4 TRIAL DESIGN  
4.1 Description of Trial Design  
This is a single arm, international, multicenter trial of tisotumab vedotin in patient s with recurrent or 
metastatic cervical cancer who have received at least on e prior line of sys temic therapy . Eligible 
patient s will be treated with IV tisotumab vedotin 2 .0 mg/kg  1Q3W . Imaging will be obtained every 
6 weeks  for the first 30 weeks and then every 12  weeks thereafter , calculated from the date of first 
IMP dosing. Imaging should continue until the patient experiences IRC verified disease progression, 
begins a new anti -cancer therapy, withdraws from the trial or dies , whichever comes first . For patients 
who achieve a  response, a repeat scan must  be obtained no earlier than 4  weeks (28 days) after the 
first scan to confirm the  response.  Survival status will be assessed every 60 days ( 7 days) , beginning 
from the day of last IMP dose,  or more frequently around the time of a database lock. Approximately 
100 patient s will be enrolled in  the trial.   
The design of the trial is shown in Figure 4-1.  
 
Figure 4-1 Trial Design  
4.2 Trial Design Rationale  
Data from GEN701 part II demonstrate substantial efficacy of tisotumab vedotin in previously  treated 
patients with recurrent or metastatic cervical cancer along with a manageable safety profile. Among 
the first 34 cervical cancer patients in the expansion cohort of GEN701 there were 9 confirmed 
responses (26%) which suggest a substantial improvem ent over available treatment options in this 

Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  28 population of great medical need. In addition, substantial tumor regression in this setting can be 
presumed to be attributed to treatment  with tisotumab vedotin . 
Based on the above, it is warranted  to further st udy the efficacy and safety of tisotumab vedotin in a 
larger cohort of previously treated patients with recurrent or metastatic cervical cancer using a single -
arm study design.  
In order to minimize any bias in progression assessments, patient s who discontinue the IMP  due to a 
non-progression event (e .g. toxicity), will be required to continue imaging (according to the 
Q6W /Q12W  schedule ) until radiographic progression is verified by the independent review 
committee ( IRC) and/or a new anti -cance r therapy is initiated.  
4.3 Dose and Schedule Rationale  
Patient s in this trial will be treated with 2.0 mg/kg 1Q3W . The 2.0 mg/kg dose  was identified as the 
Recommended Phase 2 Dose in GEN701 part I and was further evaluated in multiple dose expansion 
cohorts during which additional safety and efficacy data were collected . Please refer to the 
Investigator’s Brochure . 
4.4 End of Trial  and Treatment Discontinuation Definitions  
4.4.1 End of Trial 
The trial is considered completed when  the last patient die s or with draws from the trial OR tisotumab 
vedotin  is commercially available . However, maximal trial duration is 5 years (starting from when the 
first patient signs the ICF).  
4.4.2 Treatment  Discontinuation  
Treatment should continue until the patient fulfills one of the treatment discontinuation criteria (please 
see Section  8.1).  
4.4.3 Trial Termination  
The sponsor reserves the right to close the trial site or terminate the trial at any time for any reason at 
the sole discretion of the sponsor. Trial sites will be closed upon trial completion.  
The investigator may initiate trial site  closure at any time, provided there is reasonable cause and 
sufficient notice is given i n advance of the intended termination.  
Reasons for the early closure of a trial site by the sponsor or investigator may include but are not 
limited to:  
 Failure of the investigator to comply with the protocol, the requirements of the IEC/IRB or local 
health  authorities, the sponsor's procedures, or GCP guidelines . 
 Inadequate recruitment of patient s by the investigator . 
 Discontinuation of further tisotumab vedotin  development . 
o If the development of the tisotumab vedotin  is discontinued, and trial closure is necessary, 
sponsor will ensure provisioning of post trial treatment for ongoing trial patients.  
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  29 5 TRIAL POPULATION  
5.1 Inclusion Criteria  
Each patient  must satisfy all  of the following criteria to be enrolled in the trial.  
1. Patients with extra -pelvic metastatic o r recurrent cervical cancer with squamous cell, 
adenocarcinoma or adenosquamous histology, that:  
a. Have experienced disease progression during or after treatment with:  
i. Paclitaxel+cisplatin or carboplatin  
OR 
ii. Paclitaxel+topotecan,  
 
in combination with bevacizu mab unless patients are ineligible for bevacizumab 
treatment according to local standards.  
b. Have received no more than 2 prior systemic treatment regimens for recurrent or 
metastatic cervical cancer. Chemotherapy administered in the adjuvant or neoadjuvant 
setting, or in combination with radiation therapy should not be cou nted as a prior 
systemic treatment regimen.  
c. Are not candidates for curative therapy, including but not limited to, radiotherapy or 
exenterative surgery.  
2. Measurable disease according to RECIST v1.1 as assessed by IRC. 
3. Age ≥ 18 years.  
4. Acceptable renal function: Calculated (Cockcroft -Gault)  Glomerular Filtration Rate (GFR)  
> 50 mL/min.  
5. Acceptable liver function: Alanine aminotransferase (ALT) and aspartate aminotransferase 
(AST) ≤  3 times the upper limit of normal (ULN) (if liver tumor/metastases are present, then 
≤ 5  ULN is allowed); bilirubin ≤  1.5  ULN, except in patient s diagnosed  with Gilbert’s 
syndrome, direct bilirubin ≤  2  ULN.  
6. Acceptable hematological status: Hemoglobin ≥  5.6 mmol/L (9.0  g/dL), absolute neutrophil 
count (ANC) ≥  1500/µL (1.5 109/L); platelet count ≥  100109/L assessed at least 2 weeks 
after transfusion with bl ood products and/or growth factor support .  
7. Acceptable coagulation status : 
a. For patients not on anti -coagulation therapy : 
i. Activated partial thromboplastin time (aPTT) ≤  1.25 ULN.  
ii. International normalized ratio (INR) ≤  1.2 
b. For patients on anti -coagulation therapy:  
i. aPTT ≤  1.25 ULN.  
ii. INR:  Patients on anti -coagula nts that requir e laboratory assessments for dose 
titration (warfarin  or other Vitamin K dependent anti -coagulant agents ) must 
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  30 be on a steady dose (no active titration) for ≥ 4 weeks prior to first plan ned 
administration  of tisotumab vedotin  and must have an INR ≤  2.5 for 
eligibility.  
iii. Patients on anti -coagul ants that do not require laboratory assessments for dose 
titration do not need to be on a st eady  dose for ≥  4 weeks prior to first planned 
administr ation  of tisotumab vedotin .  
iv. Concurrent chronic  use of prophylactic AcetylSalicylic Acid (ASA, e.g., 
aspirin) is prohibited for patients on any type of anti -coagulation therapy.  
 
8. Eastern Cooperative  Oncology Group (ECOG) performance status of 0 or 1  prior to the first 
planned administration of IMP .  
9. Life expectancy of at least three months.  
10. A negative serum pregnancy test for patients of reproductive potential. Patients that are 
postmenopausal or permanently sterilized (please refer to Section 10.1.5  for definitions), can 
be considered as not having reproductive potential.  
11. Patients of reproductive potential must agree to use adequate contracepti on during and for 6 
months after the last IMP administration. Adequate contraception is defined as highly effective 
methods of contraception (please refer to Section 10.1.5  for more information). In countries 
where two highly effective methods of contraception are required this will be an inclusion 
criterion.  
12. All p atients  must agree not to donate eggs  (ova, oocytes) for the purpose  of assisted 
reprodu ction during the trial and for 6 months after receiving the last dose of IMP.  
13. All patients must provide a fresh or archival biopsy  prior to the first planned administration of 
IMP, unless determined it is unfeasible after sponsor medical review. For specif ic tissue 
requirements, please refer to Section 9.7.3 . 
14. Following receipt of verbal and written information about the trial, patient s must provide 
signed informed consent before any trial -related activity is carried out.  
5.2 Exclusion Criteria  
Any patient  who meets any of the following criteria  will be excluded from participatin g in the trial.  
1. Patients with primary neuroendocrine or sarcomatoid histologi es. 
2. Hematological:  
a. Known past or current coagulation defects leading to an increased risk of bleeding . 
b. Diffuse alveolar hemorrhage from vasculitis . 
c. Known bleeding diathesis . 
d. Ongoing major bleeding . 
e. Trauma with increased risk of life -threatening bleeding . 
f. History of severe head trauma or intracranial surgery within 8 weeks  of trial entry.  
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  31 3. Cardiovascular:  
a. Clinically significant cardiac disease including unstable angina, acute myocardial 
infarction 6 months prior to screening . 
b. Any medical history of  congestive heart failure (Grade III or IV as classified by the 
New York Heart Association ). 
c. Any medical history of decreased cardiac ejection fraction of <  45%. 
d. A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a 
QTc inter val >450 msec) . 
e. A complete left bundle branch block (defined as a QRS interval ≥  120 msec in left 
bundle branch block form) or an incomplete left bundle branch block.  
4. Central nervous system: Any history of intracerebral arteriovenous malformation, cerebral  
aneurysm, or stroke (transient ischemic attack >  1 month prior to screening is allowed).  
5. Ophthalmological: Active ocular surface disease at baseline. Patients with any prior episode 
of cicatricial conjunctivitis or Steven Johnson syndrome  are ineligible . 
6. Other cancer: Known past or current malignancy other than inclusion diagnosis, except for: 
Non-invasive basal cell or squamous cell skin carcinoma; noninvasive, superficial bladder 
cancer; any curable cancer with a complete response (CR) of  ≥ 5 years durat ion. 
a. Brain metastases  are allowed  if the following criteria are met : Definitive therapy (for 
example: surgery or stereotactic brain radiotherapy) has been completed > 8 week s 
before the first dose of IMP; no evidence of clinical or radiologic progression  of the 
brain metastases ; patients have completed perioperative corticosteroid therapy or 
steroid taper. NOTE: Chronic steroid therapy is acceptable provided that the dose is 
stable for 1 month prior to screening.  
7. Surgery/procedures: Major surgery within 4  weeks or minor surgery  within 7  days prior to  the 
first IMP administration . Patient s who have planned major surgery during the treatment period 
must  be excluded from the trial.  
8. Peripheral neuropathy grade > 2. 
9. Prior therapy : 
a. Any prior treatment with  MMAE -derived drugs . 
b. Radiotherapy within 21 days prior to the first administration of IMP. Patients must 
have recovered from all clinically significant radiation -related toxicities. At least 42 
days must have elapsed from the last administration of chemo -radiotherapy.  
c. Small molecules, chemotherapy, immunotherapy, monoclonal antibodies , or any 
experimental agents (not specified in this protocol) within 28 days prior to the first 
administration of IMP . 
10. Other:  
a. Ongoing significant, uncontrolled medical conditio n. 
b. Clinically significant active viral, bacterial or fungal infection requiring IV or oral 
treatment with antimicrobial therapy ending less than 7 days prior to first IMP 
administration . 
c. Clinically relevant b ilateral hydronephrosis which cannot be alleviat ed by ureteral 
stents or percutaneous drainage . 
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  32 d. Patients with clinical symptoms or signs of gastrointestinal obstruction and who 
require parental hydration and/or nutrition . 
e. Inflammatory bowel disease including Crohn's disease and colitis ulcerosa  
f. Ongoing acute or chronic inflammatory skin disease . 
g. Inflammatory lung disease including moderate and severe asthma and chronic 
obstructive pulmonary disease (COPD) requiring chronic medical therapy .  
11. Known  seropositivity  of human immunodeficiency virus; known medi cal history or ongoing 
hepatitis B or C infection . 
12. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (dosing 
exceeding 10 mg daily of prednisone or equivalent) or any other form of immunosuppressive 
therapy within 7 days prior to  the first dose of tisotumab vedotin.  
13. Patient is p regnan t, breast feeding  or intends to conceive children  starting from date of signed 
ICF and continuing until  6 months after the last dose of  trial treatment . 
14. Patient  has any condition for which, in the opinion of the investigator, participation would not 
be in the best interest of the patient  (e.g. compromise the well -being) or that could prevent, 
limit, or confound the protocol -specified assessments.  
15. Patient  has known allergies, hypersensitivity, or intolerance to tisotumab vedotin or its 
excipients  (please refer to the Investigator's Brochure) . 
5.3 Screen Failures  
Screen failures are defined as patients who consent to participate in the clinical trial but are no t 
subsequently entered in the trial. Minimal information  about the patient and the reason for screen 
failure should be recorded in the eCRF  in order to meet   the Consolidated Standards of Reporting 
Trials (CONSORT) publishing requirements.  
Individuals who do not meet the criteria for participation in this trial (screen failure s) may be 
rescreened. The rescreening must be approved by the sponsor to ensure that the safety of the patient 
is not compromised.  
Upon rescreening , all eligibility criteria must be re -assessed  by investigator. Results from assessmen ts 
performed during the previous screening period are acceptable  for rescreening purposes  if performed 
within the specified time frame and the inclusion/exclusion criteria is met : Previous submitted/IRC 
evaluated CT/MRI scans are val id for rescreening purposes  as long as the scanning acquisition date is 
≤ 28  days prior to cycle 1 day 1. Already completed Health Related Quality of Life (HRQL)  
questionnaires and baseline ophthalmological evaluations are valid  as long as they have been 
completed  ≤ 28 days prior to cycle 1 day 1 . Blood samples  taken during the previous screening  process  
are valid for rescreening  purposes  as long as they are fulfilling the initial timelines as indicated in 
Table 1-1. If previously approved for eligibility, the same tumor biopsy sample is valid for rescreening 
purposes.   
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  33 6 TREATMENT  
6.1 Treatment Assignment  
6.1.1 Patient Numbering  
After signing the informed consent  form (ICF) , a screening number is assigned to the patient. Patients 
that meet the eligibility criteria and are enrolled  will be assigned a patient number.   
6.1.2 Treatment Assignment  
This is an open -label single -arm trial and all patients will be assigned to the same treatment (Section 
6.2). 
Trial participation begins once written informed consent is o btained.  
6.2 Dosage and Administration  
6.2.1 IMP  
Tisotumab vedotin at 2.0 mg/kg will be administered as an IV infusion over  a minimum  of 30 minutes 
on day 1 of each treatment cycle (one treatment cycle is 21 days).  It is recommended that the infusion 
completes withi n 60 minutes.  
Each patient’s dose will be calculated based on the patient’s weight (please refer to Section 9.3.2  for 
more details on assessment of weight) rounded to the  nearest kilogram,  
i.e., 2.0 mg/kg × body weight in kg. For patients  who weigh > 100 kg, the calculation of IMP dose 
should be normalized to 100 kg (i.e. , 2.0 mg/kg × 100 kg = 200 mg).  
Preventive eye therapy must  be administered in relation to each infusion  as described below . 
6.2.2 Pre-medication  
MANDATORY Prophylaxis of Ocular Adverse Events : 
In order to prevent ocular adverse events , all patient s must adhere to the below ocular pre -medication 
guidelines:  
 Use of preservative -free lubricating eye drops  during the whole treatment phase of the trial (i.e.  
from  first dose  of IMP until 30 days after last dose of IMP ).  
 Application of steroid eye drops  during the first 3 days of each treatment cycle (i.e. first drop to 
be given prior to start of infusion; continue treatment for 72h thereafter).   
 Administration of local ocular vasoconstrictor before infusion . If the patient does not tolerate 
ocular vasoconstrictors due to adverse reactions, continued treatme nt with these may be stopped 
at the discretion of the investigator and following discussion with the sponsor ’s Medical Officer.  
 Use of eye cooling pads during the infusion . 
 It is recommended not to wear  contact lenses during the whole treatment phase of t he trial.  
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  34 Please refer to the Preparation and Administration Guide  for more detailed instructions.  
Please note that prophylactic pre -medication do es not qualify as an intervention when assessing  
CTCAE  grading of treatment emergent  ocular  adverse event s. 
Please refer to Section 7.2.1.1  for more information about mitigation of ocular adverse events . 
6.2.3 Supportive Care  
Prophylaxis of alopecia:  
Suggest using the DigniCap Scalp Cooling System according to guidelines 
(https:// www.d ignicap.com /) to prevent chemo -induced hair loss.  
Prophylaxis of recurrent infusion related reactions  (IRRs) :  
In case of an IRR ≥ grade 2, the patient should  be pre -medicated prior to next infusion of IMP 
(antihistamine, acetaminophen and corticosteroids are recommended) . 
Please refer to Section 7.2.2  for more information about mitigation of IRRs.  
Prophylaxis of nausea:  
Prophylactic t reatment with ant i-emetics  is strongly suggested for  patient s experiencing  an adverse 
event of nausea  after cycle 1.   
Prophylaxis of recurrent neutropenia:  
In case of an AE of neutropenia grade 3 or grade 4, g rowth factor support (G -CSF) should  be given 
prophylactically for subsequent IMP administrations.  
Please refer to Section 7.2.2  for more information about mitigation of AEs of neutropenia . 
6.3 Compliance  
The IMP  will be administered in the controlled environment of a clinical research center, and the 
direct observation of the administration of the IMP by the trial staff will ensure compliance with trial 
requirements. The date and time of each IMP administration must  be captured  in the  eCRF.   
6.4 Concomitant Medication s and Therapies  
6.4.1 Permitted Concomitant Medications and Therapies  
Anti-coagulation therapy is permitted. Patients  being treated with anti-coagulation therapy  that 
requires laboratory assessments for dose titr ation (warfarin or other Vitamin K dependent 
anticoagulant agents)  should have their doses adjusted to target an INR  2.5. Coagulation parameters, 
including aPTT, PT and INR, must  be measured locally  prior to each infusion of tisotumab vedotin  as 
per the protocol flowchart (Table 1-1). 
6.4.2 Permitted Concomitant Therapy Requiring Caution and/or Action  
Drugs and substances known to be strong CYP3A and/or P -gp inhibitors according to the FDA’s list 
of drug interactions  should be  avoided if possible ( FDA, 2016 ). If administered, the patient must be 
closely observed for potential adverse reactions.  
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  35 6.4.3 Prohibited Concomitant Therapy  
Patient s must be instructed not to take any medications, including over -the-counter products, without 
first consulting with the investigator.  
The following is prohibited:  
 Chronic prophylactic treatment with AcetylSalicylic Acid (ASA, e.g., aspirin) in combination 
with any other anti -coagulation therapy .  
 Radiotherapy .   
o Radiation therapy of a  symptomatic solitary non -target lesion IS allowed.  
 Small molecules, chemotherapy, immunotherapy, monoclonal antibodies, other MMAE -derived 
drugs or any experimental agents  (not specified in this protocol) . 
6.5 IMP  Information  
6.5.1 Physical Description of the IMP  
Tisotumab vedotin is presented as a lyophilized cake for reconstitution in water for injection and is 
intended for dosing by the intravenous route by infusion after dilution in physiological saline solution. 
It will be manufactured an d provided under the responsibility of the sponsor. A list of excipients can 
be found in the Investigator’s Brochure.  
6.5.2 Packaging  
Tisotumab vedotin will be supplied to the trial site  pharmacy as bulk supply cartons.  
The IMP will be supplied in vials containing 40  mg of tisotumab vedotin as lyophilized powder. The 
powder must  be reconstituted with 4  mL water for injection leading to a 10  mg/mL solution.  
The IMP  will not be dispensed in child -resistant packaging.  
6.5.3 Labeling  
Labeling will be in accordance  with the EU Guidelines to Good Manufacturing Practice, Annex  13, 
Investigational Medicinal Products, and any other applicable local regulatory requirements.  For 
further details, see the trial specific preparation and administration guideline.  
6.5.4 Preparation,  Handling and Storage  
Tisotumab vedotin (lyophilized vials) must  be stored in a refrigerator at 2°C to 8°C.  
The dose of tisotumab vedotin for administration must be prepared by the trial site  pharmacy using 
aseptic technique.  
The reconstituted tisotumab vedotin must  be diluted into 0.9%  NaCl 100  mL infusion bag according 
to the dose calculated for the patient . 
A 0.2 µm in-line filter must be used for the infusion. The entire 100  mL infusion volume from the 
prepared infusion bag needs to be administered, n o dead volume is provided.  
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  36 Please refer to the administration and preparation  manual for instructions on storage, preparation and 
infusion.  
6.5.5 Drug Accountability  
The investigator or designee must maintain an accurate record of the shipment and dispensing of IMP 
in a drug accountability log. Drug accountability will be noted by the field monitor during trial site  
visits and at the completion of the trial.  
It is forbidden to use the IMP  for purposes other than as defined in this protocol.  
When drug accountabil ity has been verified and a copy of the completed drug accountability log  has 
been received by sponsor , the investigator will dispose  all used and unused trial treatment and 
packaging  in accordance with the guidance in the administration and preparation ma nual and local 
regulations . 
6.5.6 Handling of Other Trial Treatment  
Not applicable.  
6.6 Technical  Complaint Handling  
A technical  complaint is defined as any suspicion of a product defect related to manufacturing, 
labeling, or packaging, i.e. any dissatisfaction rela tive to the identity, quality, durability, or reliability 
of a product, including its labeling or package integrity. A technical complaint  may have an impact 
on the safety and efficacy of the product. Timely, accurate, and complete reporting and analysis o f 
technical complaint  information from trials are crucial for the protection of patient s, investigators, and 
the sponsor, and are mandated by regulatory agencies worldwide. The sponsor has established 
procedures in conformity with regulatory requirements w orldwide to ensure appropriate reporting of 
technical complaint  information; all trials conducted by the sponsor or its affiliates will be conducted 
in accordance with those procedures.  
6.6.1 Procedures  
All initial technical complaint s must be reported to the sponsor by the trial site  personnel within 
24 hours after being made aware of the event.  
If the defect is combined with a SAE , the trial site  personnel must report the technical complaint  to 
the sponsor according to the SAE  reportin g timelines (Section 10.3). A sample of the suspected 
product must  be maintained for further investigation if requested by the sponsor.  
6.6.2 Contacting Sponsor Regarding Product Quality  
The names (and corresponding telephone numbers) of the individuals who must  be contacted 
regarding technical complaint  issues are listed on the contact information page(s), which will be 
provided as a separate document.  
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  37 7 DOSE  MODIFICATIONS AND S AFETY MANAGEMENT GUI DELINES  
7.1 Dose Modification Guidance  
7.1.1 Dose Reduction  
For patient s who do not tolerate the protocol -specified dosing schedule, dose reductions  are permitted 
in order to allow the patient  to continue  treatment  with tisotumab vedotin . Dose  reductions  must  be 
preapproved by the sponsor ’s Medical Officer  unless allowed according to the mitigation plans 
specified in the protocol  (please refer to Section 7.2). 
In case any dose  reduction of tisotumab vedotin  is needed, the dose must  be reduced according to the 
guidelines provided below ( Table 7-1). 
Table 7-1 Dose Modification Scheme  
Previous dose of tisotumab vedotin  Reduced dose of tisotumab vedotin  
 2.0 mg/kg   1.3 mg/kg  
 1.3 mg/kg   0.9 mg/kg * 
* No more than 2 dose reductions of tisotuma b vedotin will be permitted. If an AE recurs after the second dose reduction 
of IMP, then the patient  must permanently discontinue  IMP treatment.   
7.1.2 Dose delay  
For any dose delay due to  adverse events, d osing  with tisotumab vedotin  can be resumed immediately 
after the adverse event has improved  (please refer to Section 7.2 for handling adverse events with a 
protocol mitigation plan). Treatment with tisotumab vedotin  must  be permanently discontinued for 
any d ose delay > 12 weeks, (i.e. 84 days calculated from th e intended day of the next scheduled dose ), 
unless approved by the s ponsor .  
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  40  Use of eye cooling pads during the infusion.  
 It is recommended not to wear  contact lenses during the whole t reatment phase of the trial.   
Please refer to the Preparation and Administration Guide  for more detailed instructions.  
7.2.1.2  Guidelines for Treatment Prescribed by the Ophthalmologist  
Ocular symptom 
(CTCAE grading)  Treatment guideline  
(The length of treatment is to be decided by the local ophthalmologist)  
Conjunctivitis  gr 1 Frequent dosing of preservative -free topical steroid drops  is 
recommended . 
Conjunctivitis  gr 2 Frequent dosing (every second hour) of preservative -free topical steroid 
drops in conjunctio n with preservative free antibiotic prophylaxis such 
as chloramphenicol  is recommended . 
Conjunctivitis  gr 3 Frequent dosing (every second hour) of preservative -free topical steroid 
drops in conjunction with preservative free antibiotic prophylaxis such 
as chloramphenicol  is recommended . 
Keratitis  gr 1 Frequent dosing of preservative -free topical steroid drops  is 
recommended . 
Keratitis  gr 2 Frequent dosing (every second hour) of preservative -free topical steroid 
drops in conjunction with preservative free  antibiotic prophylaxis such 
as chloramphenicol  is recommended . 
Conjunctival    
ulceration: Any grade  Frequent dosing (every second hour) of preservative -free topical steroid 
drops in conjunction with preservative free antibiotic prophylaxis such 
as chlora mphenicol  is recommended . 
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  44  Any dose delay > 12 weeks  calculated from the intended day of the next scheduled dose , unless 
approved by the sponsor . 
 
IMP discontinuation criteria for other adverse events:  
 Any grade  pulmonary or CNS hemorrhage.  
 Second occurrence of a grade 3 infusion related reaction (despite pre -medication) . 
 First occurrence of a ≥ grade 4 infusion related reaction . 
 First occurrence of muc ositis ≥ grade 4 . 
 First occurrence of peripheral neuropathy ≥ grade 4 . 
 Any dose delay > 12 weeks calculated from the intended day of the next scheduled dose , unless 
approved by the sponsor . 
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  45 8 DISCONTINUATION , FOLLOW -UP AND COMPLETION  
8.1 Discontinuation of Treatment  
A patient’s trial treatment must be discontinued  if one of the following criteria is met : 
 Radiographic disease progression verified by IRC.  
 Death.  
 Unacceptable AEs requiring treatment discontinuation .  
 Investigator believes that it is in the best  interest of the patient to stop treatment.  
 Withdrawal of consent.  
If IMP treatment is permanently discontinued for other reasons than IRC verified disease progression, 
every effort should be made to continue tumor assessments as outlined in Table 1-1. 
 
Discontinuation and safety follow -up visit:  
When IMP treatment is permanently discontinued, invest igators will perform a  treatment 
discontinuation visit and a safety follow -up visit. The treatment discontinuation  visit should  be 
performed as soon as possible  after permanent discontinuation of IMP  (preferably within 7 days after 
treatment discontinuation has been decided)  and will include most assessm ents performed during  
screening (Table 1-1). The safety follow -up visit should be performed 30 days (±5 days) after the 
patient has received the last do se of IMP  (Table 1-1).  
 
Survival follow -up: 
All patients will be followed until  death or withdrawal from the trial.  Information about survival status 
and initiation of any new anti -cancer therapy should be collected every 60 days (±7days)  (or more 
frequently around the time of a database lock ), begin ning from the day of last IMP dose. Survival 
follow -up can be performed  by telephone contact (the patient or a family member  may give the 
requested  information) or during a routine visit, if such a visit is scheduled for other reasons not related 
to this trial.  This should be documented in the medical records.  
 
8.2 Withdrawal fro m the Trial  
A patient  may withdraw  from the trial for any of the following reasons:  
 Withdrawal of consent  to participate . 
 Investigator  decision.  
 Lost to follow -up. 
Optional research samples collected from patients that withdraw from the trial will be retained and 
used in accordance with the patient’s original separate informed consent unless this consent is revoked  
(see Section 8.3). 
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  46 8.3 Withdrawal f rom the Optional Research Samples  
The patient may revoke their  consent for optional research samples at any time . In this case, the 
optional research sample s will be destroyed  and no further testing will take place. To initiate the 
sample destruction proces s, the investigator must notify the sponsor of withdrawal of consent for the 
optional research samples and to request sample destruction. The sponsor will  then initiate the process 
for sample destruction. If requested, the investigator will receive written  confirmation from the 
sponsor that the sample s have  been destroyed.  
8.4 Withdrawal from the Use of Samples in Future Research  
The patient  may withdraw consent for use of samples for research (Section 13.2.5 ). In this case, 
samples previously collected will be destroyed after they are no longer needed for the clinical trial. 
Details of the sample retention for research are presented in the main ICF.  
8.5 Follow -up for Safety Evaluations  
A safety follow -up visit must be performed 30 days (± 5 days) after the patient has received the last 
IMP dose (Table 1-1). Please see Section 8.1 for further details.  
8.6 Lost to Follow -up 
For patients whose status is unclear because they fail to appear for trial visits  without stating an 
intention to withdraw consent, the investigator must  show "due diligence" by contacting the patient, 
family or family physician as agreed in the ICF and by documenting in the source documents steps 
taken to contact the patient, e.g. dates of telephone calls, registered letters, etc. A patient must  not be 
considered lost to follow -up until due diligence has been completed  (where possible, 3 telephone c alls 
and, if necessary, a certified letter to the patient ’s last known mailing address or local equivalent 
methods) . Patients lost to follow -up must  be recorded as such on the appropriate disposition eCRF.   
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  47 9 TRIAL  ASSESSMENTS  
9.1 Demography and Baseline Assessm ents 
9.1.1 Demographics  
Demographic details must be assessed and recorded in the eCRF  at screening.  
9.1.2 Medical History  
Medical history is defined as a ll relevant past and all current medical conditions/diseases  (besides 
cervical cancer)  occurring  prior to the patie nt signing the ICF .  
9.1.3 Concomitant Medication  
Investigators may prescribe concomitant medications or treatments deemed necessary to provide 
adequate supportive care except for those medications identified as “prohibited” (Section  6.4.3 ).  
The patient  should  be told to notify the trial site  about any new medications she is taking . All 
medications  and significant non -drug therapies (including physical therapy, herbal/natural 
medications and blood transfusions) administered during the trial must be recorded in the eCRF  from 
28 days prior to the first dose of IMP and up to 30 days after the last dose of IMP . Thereafter only  
new anti -cancer therapy (s) will be collected . 
9.1.4 Prior Cancer Therapy and Surgery  
All anti-cancer  therapies (including surgery, radiotherapy, chemo -radiotherapy, systemic treatment 
regimens etc.), received by the patient,  from the time of the initial cervical cancer diagnosis  until 
enrollment in this trial, should  be reported in the appropriate section of the eCRF.  
9.2 Efficacy assessments  
9.2.1 Tumor imaging :  
Tumor response will be assessed  both locally and centrally according to RECIST v1.1 criteria 
(Eisenhauer et al., 2009 ). All tumor  imaging data  obtained locally  (including unscheduled scans)  
during the trial  should  be submitted to the Imaging CRO for review by the IRC.  Data obtained from 
central IRC  review will be used in the analysis and reporting of trial results.  
Tumor imaging is strongly preferred to be acquired by computed tomography (CT). For the abdomen 
and pelvis, contrast -enhanced magnetic resonance imaging (MRI) may be used when CT with 
iodinated contrast is contraindicated, or when mandated by local practice. A contrast enhancing  MRI  
is the preferred modality for imaging the brain ( if contraindicated, an MRI without contrast or CT 
with/without contrast is acceptable ). The same imaging moda lity and ideally the same scanner should 
be used throughout the trial to optimize the reproducibility of the assessment and preserve the accuracy 
of the assessment of response or progression.  
Combined PET/CT may be used only if the CT portion is of similar  diagnostic quality to CT alone.  
At the discretion of the investigators, FDG -PET scans may be performed to document disease 
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  48 progression as per RECIST v1.1 (Eisenhauer et al., 2009) . Localized CT, MRI or X -rays must be 
acquired for assessment of  skeletal lesions not visible on other images . 
Chest X -rays and ultrasound should not  be used to measure tumor lesions.  
9.2.1.1  Baseline Imaging Assessments  
Baseline i maging assessments will be perfor med during the screening period (≤  28 days prior to cycle 
1 day 1). Any imaging assessments already completed for regular  radiographic  evaluation of the 
patient’s cancer disease ca n be considered as the baseline images for this trial  as long as they are of  
diagnostic quality  and have been obtained ≤ 28 days prior to cycle 1 day 1 . The following assessments 
are required at baseline:  
 Chest X -ray   
o The chest X -ray (CXR ) should be locally evaluated : If the CXR shows evidence of metastatic 
disease, a CT of the c hest must be obtained and submitted to the Imaging CRO for evaluation 
of measurable disease and should continue to be obtained for evaluation of  response . If the  
CXR does not show any e vidence of metastatic disease, further imaging of the chest does not 
need to continue . 
o Chest CT images may be used for evaluation of baseline chest/lung metastasis  instead 
of CXR  if such images have been obtained ≤ 28 days prior to cycle 1 day for reasons 
not related to this trial .  
 
 Abdomen and pelvis CT or MRI scan .  
o The CT/MRI scan of the abdomen and pelvis  must be submitted to the Imaging CRO for 
evaluation of measurable disease  and should continue to be obtained for evaluation of response .  
 
 If clinically indicated, CT or MRI of other areas of malignant disease  (e.g. neck  or brain ) must be 
performed  and submitted to the Imaging CRO  for evaluation of measurable disease and should 
continue to be obtained for evaluation of response .  
 
Determination of measurable disease:  
All patients must have measurable disease as defined by RECIST v1.1 using conventional imagin g 
techniques such as CT or MRI. Measurable disease is defined as at least one target lesion that can be 
accurately measured in at least one dimension. If using a CT with a slice thickness of less than 5 mm 
or MRI, non -lymph node lesions must measure ≥10 mm in the longest diameter and lymph nodes must 
measure ≥15 mm in the shortest diameter. Lymph nodes that measure less than 10 mm in the short 
axis are deemed “non -pathologic.” Lymph nodes that measure >10 mm b ut <15 mm should be 
classified as non -target lesions. It is strongly recommended that MRI is used for evaluation of  lesion(s) 
present within an irradiated field. Tumors within a previously irradiated field will be designated as 
“non -target” lesions unless progression is documented or a biopsy is obtained to confirm persistence 
at least 90 days following completion of radiation therapy.  Biopsy confirmation MAY be considered 
for either target or non -target lesions if the lesion(s) measures <30 mm or if the tr eating physician 
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  49 determines it is clinically indicated.  If a biopsy is performed on a previously irradiated lesion , a MRI  
scan (CT if MRI is contraindicated) should be obtained as baseline evaluation after the biopsy 
procedure . 
Baseline images must be subm itted to the Imaging CRO in order to verify that the patient meets the 
inclusion criterion of m easurable disease . The baseline imaging will undergo expedited review by the 
IRC (approximately within 3 days starting from the time of image receipt  and once al l queries issued 
by the Imaging CRO  have been  resolved ). Baseline images should be submitted for IRC review as 
soon as possible after the screening process has been initiated in order to prevent any delay of first 
dosing. The results of the central IRC bas eline review will be directly communicated to the trial site.  
9.2.1.2  Post-baseline Imaging Assessments  
Imaging assessments must be performed every 6 weeks (±7 days) for the first 30 weeks and every 12 
weeks (±7 days) thereafter , calculated from the date of first  IMP dosing . Imaging should continue 
until the patient experiences IRC verified disease progression, begins a new anti -cancer the rapy, 
withdraws from the trial or dies , whichever comes first . For patients who achieve a response, a repeat 
scan must be obtai ned no earlier than 4 weeks (28 days) after the first scan to confirm the response . 
For stable disease (SD), measurements must have met the SD criteria at least 5 weeks after the first 
dose of trial treatment.  Time points for radiographic evaluation should  be calendar based and does not 
depend on cycle visits i.e. radiological evaluation must be perfor med regardless of IMP administration 
delays.   
 NOTE: For p atients who permanently discontinue IMP for other reasons  than IRC verified 
disease progression ( e.g. adverse events ), every effort should  be made to  continue on-trial 
radiological evaluati on as outlined in Table 1-1. 
All post -baseline images must be submitted to the Imaging CRO for review by the IRC.  Post-baseline 
imag es (except cases of locally determined disease progression – please see details for exp edited 
review below) will be read on an ongoing basis as detailed in the CRO Imaging M anual . Results of 
post-baseline  readings will not be communicated to the trial sites  (unless the site requests verification 
of suspected progressive disease) . 
Additional imaging assessments may be performed at any time during the trial at the investigator’s 
discretion to support the efficacy evaluations for a patient, as necessary. If any supplemental 
radiological evaluation is performed off-schedule , subsequent imaging as sessments must  be 
performed in accordance with the original imaging schedule  (please refer to Table 1-1). All 
supplemental images  must be submitted to the Imaging CRO for review.   
Determination of  Disease Progression  
In case d isease progression  is determined by the local investigator , the images must be transferred to 
the Imaging CRO for expedited review  by the IRC . The investigator  seeking an expedited review 
should  indicate this request to the Imaging CRO on a designated form . In all  instances, the process at 
the Imaging CRO will ensure that the central IRC reviewers remain blinded to the results of the local 
assessment and any pot ential expedited nature of the review. The result of the central IRC review will 
be communicate d directly  to the trial site .  
NOTE: Every effort should be made to continue the patient on IMP treatment during the IRC review 
period, as long as it is clinical ly acceptable.  
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  50 In case progressive disease is verified by IRC:  
If the central  IRC review verifies  disease progression, the patient must permanently discontinue IMP 
treatment . No s ubsequent tumor assessments are required.  
In case progressive disease not is verified by the IRC:  
If the central  IRC review  does not verify disease progression , every effort must  be made to continue 
IMP treatment , as long  as it is clinically acceptable.  Patient s should continue on-trial radiological 
evaluation.  
9.2.2 Survival Status  
Survival status will be assessed every 60  days (± 7 days) , beginning from the  day of last IMP dose 
and continues until the patient dies or withdraws from the trial . Survival status may be requested more 
frequently around the time of a database lock. Patien ts who are not or whose designated family 
members are not available for this assessment should be entered as “lost to follow -up” (Section  8.6).  
9.3 Clinical Safety Assessments  
9.3.1 Physical Examination  
A complete physical examination will at a minimum include general appearance of the following body 
systems : Lymph node region s, mouth and throat, lungs, cardiovascular, abdomen, extremities 
(including muscular -skeletal system), neurological system and skin.   
9.3.2 Body Measurements  
Height should be measured at screening . Body weight should be measured as indicated in Table 1-1.  
The patient’s body weight should be measured and used to calculate the dose of tisotumab vedotin for 
infusion. Please note that the weight measurement that is used for calculati on of dose should be the 
weight/value that is recorded in the eCRF. The following rules for weight measurements apply:  
 The body weight that is used for calculation of dose must be measured at the trial site ≤ 7 days 
prior to the infusion.   
 If the measure d weight does not fluctuate more than 10% from the baseline weight  (i.e., the last 
weight measurement taken before first dosing of tisotumab vedotin),  the baseline weight may be 
used for calculat ion of IMP dose. 
9.3.3 Vital Signs  
Vital signs (including temperature, blood pressure and heart rate ) must  be measured according to  
Table 1-1. The patient should  be resting for at least 10 minutes before vital  signs are measured. 
Temperature should  be measured as an oral, axillary, rectal or ear temperature.  Within  each visit, 
preferably the same equipment s hould  be used for vital sign measurements. On IMP administration  
days, vital signs must  be measured  no lo nger than 30 minutes before infusion start.  
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  51 9.3.4 Electrocardiograms  
One 12 -lead ECG must  be performed at screening. Three 12-lead ECGs  must be performed before  
and after  each administration of IMP , at additional time points during cycle 1 (please refer to Table 
1-2) and at the treatment discontinuation visit .  
All patients should be resting for at least 10 minutes prior to obtaining the ECG . In case a ny 
irregularity  (e.g., vomiting or  cough)  occurs  during the  recording of the ECG , the ECG should be 
repeat ed. All ECG  recordings should  be performed with at least 2 minutes apart in accordance with 
the ECG Specifications Manual  issued by the ECG CRO . 
The ECG recordings  should be  locally evaluated by investigator ( the investigator may delegate this 
task to a cardiologist, if applicable ) in order to exclude  any safety concerns. The ECGs must  
furthermore be transmitted  to the ECG CRO  for central review . The r esults  from the central review  
will be used in  the analyses and reporting of trial results.    
9.3.5 ECOG  
The Eastern Cooperative Oncology Group (ECOG) performance status will be assessed by the 
investigator as indicated in Table 1-1. Performance status will be scored using the ECOG performance 
status scale index  (Table 9-1). 
Table 9-1 ECOG performance status  
Score  Score  
0 Fully active, able to carry out all normal activity without restriction.  
1 Restricted in physically strenuous activity, but ambulatory and  able to carry out work of a light or 
sedentary nature, e.g., light housework, office work.  
2 Ambulatory and capable of all self -care but unable to carry out any work activities.  
Up and about more than 50% of waking hours.  
3 Capable of only limited self -care, confined to bed or chair more than 50% of waking hours.  
4 Completely disabled. Cannot carry out any self -care. Totally confined to bed or chair.  
5 Dead.  
9.3.6 Eye Examination  and Ophthalmological Evaluation  
Eye examination: Eye examination should be assessed by investigator as indicated in Table 1-1 and 
should include a visual inspection of the eye orbit and conjunctiva and  control of normal eye 
movement. The patient should furthermore be asked about any ocular symptoms (e.g. itchy eyes, 
sticky eyelids, eye secretion, blurry vision etc.)  
Ophthalmological evaluation: All patients  must have their eyes evaluated by an ophthalmo logist 
during screening as indicated in  Table 1-1. Patients  experiencing ocular symptoms  or patients with 
abnormal ocular findings at the eye examination (assessed by investigator) must be referred to an 
ophthalmologist for prompt review (pr eferably within 72 hours and no later than within one week)  
any time during trial.  The ophthalmologist’s evaluation should be recorded in the eCRF . 
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  52 9.4 Pharmacokinetics  
9.4.1 Evaluations  
Blood samples for assessment of tisotumab vedotin and MMAE will be drawn in acc ordance with the 
PK flowchart  (see Table 1-2). Two assays  will be used for tisotumab vedotin , one detecting tisotumab 
vedotin  only and one detecting tisotumab vedotin  and non -conjugated tisotumab . In addition a third 
assay will be used to determine free MMAE in circulation.  
Samples will be used to evaluate the PK of tisotumab vedotin. Remaining s amples collected for 
analyses of tisotumab vedotin plasma concentration may also be used to evaluate other safety , 
efficacy , or biomarker  lab parameters  to address concerns arising during the trial . 
9.4.2 Analytical Procedures  
Plasma samples will be analyzed to determine concentrations of conjugated and non -conjugated 
tisotumab vedotin, as well as MMAE,  using validated methods .  
9.5 Clinical Laboratory Assessments  
Central Laboratory  
The tests detailed in Table 9-2 will be drawn and shipped for centralized testing  and results will be 
reported to the investigators by the central laboratory as described in the laboratory manual . Central 
laboratory values will be used  for assessment of eligibility  (except for INR, aPTT and PT values which 
exclusively should be measured locally) and will also be used in the analyses  and reporting of the trial 
results . Central laboratory values must be reviewed by investigator prior to fi rst dosing.  
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  55 enable the ident ification of bio markers predictive of response to tisotumab vedotin. Tumor biopsies 
must  be provided  at screening , unless deemed unfeasible after sponsor medical review . Fresh biopsy 
material is preferred, but archival biopsies (FFPE blocks or slides) are also acceptable. Please note 
that any open biopsy must be performed > 7 days prior to the first IMP administration (refer to 
exclusion criteria Section 5.2). Potential mechanisms of tumor response and resistance  as well as 
treatment -induced changes in the tumor immune microenvironment , may be monitored if post-
treatment tumor biopsies are also obtained.  Optional tumor biopsies may also be collected if patients 
have unscheduled biopsies or tumor tissue resection during the course of the trial. 
9.7.1.1  Protein Expression Analyses  
TF expression and expression of other proteins related to cervical cancer bio logy or tisotumab 
vedotin’s mechanism of action  (for example; Ki -67 as a measure of proliferative index)  may be 
evaluated in tumor biopsies by IHC on an automated staining platform. Tumor sections will be scored 
by a certified pathologist, and digital imag es will be made from stained tumor sections in order to be 
used for exploratory digital pathology analyses.  
9.7.1.2  RNA Expression Analyses  
RNA sequencing and/or focused profiling may be performed  on tumor biopsies to determine TF RNA 
expression levels, and to eva luate expression of other genes such as MDR1, MDR6, Ki67 and VEGF 
associated with cervical cancer biology and/or response to MMAE/tubulin -disrupting agents for 
exploratory biomarker analyses.  RNA profiling, including a focused gene panel, may also be utilized 
to characterize the immune profile within the tumor microenvironment (T cell, B cell, dendritic cells, 
macrophage, and other immune infiltrates within the tumor) and to determine whether tisotumab 
vedotin has an effect on these immune profiles.  
9.7.1.3  DNA Analyses  
Tumor biopsies  may also be analyzed using Next Generation Sequencing (NGS) for DNA mutations, 
copy number variations, microsatellite instability, in sertions, deletions, , and/or rearran gements in 
genes  associated with tissue factor, tisotumab vedotin’s proposed mechanism of action , or cervical 
cancer biology such as tissue factor (F3 gene), -tubulin subtypes and genes involved in apoptosis 
regulation like PTEN and BCL2 . In order to conf irm genomic alterations found in tumor material, a 
normal sample (PBMC) may also be sequenced.  
9.7.2 Biomarker Assessments in Blood Samples  
Biomarker assessments will also be performed using whole blood samples to investigate potential 
pharmacodynamic markers  such as circulation TF,  and to explore the relationship to efficacy and/or 
mechanism of action of tisotumab vedotin . Assessments will be performed according to flow -chart  
(Table 1-1) in order to enable correlation analyses with response to treatment or disease progression.  
9.7.2.1  Protein Expression Analyses  
Protein levels of circulating TF and other proteins related to cervical cancer or tisotumab vedotin’s 
mechanism of action  may be m easured  so change s associated with the mechanism of action of 
tisotumab vedotin  can be monitored . 
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  56 9.7.2.2  Cell-free DNA /RNA  (cfDNA /RNA ) and Tumor -derived DNA (ctDNA) Analyses  
Circulating c ell-free DNA  and/or RNA  (cfDNA /RNA ), including circulating tumor -derived DNA 
(ctDNA)  and/or exosomal RNA (exoRNA) , may be m easured  and analyses such as  RNA expression 
levels, DNA mutations, copy number variations, microsatellite instability, indels, and/or 
rearrangements in genes  may be performed  to eva luate the association of such biomarkers with 
tisotubmab vedotin’s mechanism of action , patient response, or cervical cancer disease biology .  
9.7.3 Sample collections  
Samples for biomarker analyses  will be collected as specified in Table 1-1. 
A tumor biopsy sample must be provided at screening, unless deemed unfeasible after sponsor medical 
review. A fresh biopsy is preferred, but  archival tissue is also acceptable. The most recent archived 
biopsy should be used. Formalin -fixed, paraffin -embedded  (FFPE) blocks or 10 slides with 5 micron 
sections should be provided.  
If it is determined at any time before trial completion that additi onal material is needed from a FFPE 
tumor sample for the successful completion of the protocol -specified analyses, the sponsor may 
request that additional material be retrieved from existing samples. Also, based on emerging scientific 
evidence relating to a potential correlation between a biomarker and treatment efficacy and/or safety 
the sponsor may request additional material from previously collected tumor samples during the 
clinical trial or for a period of 5  years  after trial completion for a retrospec tive analysis. In this case, 
such analyses would be specific to research related to the IMP or diseases being investigated in the 
clinical trial.  
9.7.4 Additional Analyses  
In addition to the biomarker analyses  listed above, other biomarkers deemed relevant to ga in further 
knowledge about the pathological mechanism  of the disease or about tisotumab vedotin  (i.e. mode of 
action related effect or safety of the IMP) may be measured, based on newly emerging data from other 
ongoing trials and/or literature data. Biomarker samples may further be used to help address emerging 
issues and to enable the development of safer, more effective, and, ultimately, individualized therapy.   
Moreover, b iomarker analyses are dependent upon the availability of appropriate biomarker assays 
and clinical response rates. Biomarker analysis may be deferred or not performed, if during or at the 
end of the trial, it becomes clear that the analysis will not have sufficient scientific value for biomarker 
evaluation, or if there are not enough samples or responders to allow for adequate biomarker 
evaluation.  In the event the trial is terminated early or shows poor clinical efficacy, completion of 
biomarker assessments is based on justification and intended utility of the data.  
9.8 Pharmac ogenomic (DNA) Evaluations  
For those patients who have signed a separate consent for pharmacogenomics research, DNA /RNA  
samples (tumor and/or whole blood) may  be analyzed for DNA/RNA aberrations such as gene 
expression levels,  mutations, copy number varia tions, microsatellite instability, insertions, deletions, 
and/or rearrangements in genes  as described in previous biomarker sections.  A whole blood sample 
containing normal cells (PBMC) may also be evaluated to confirm the tumor specificity of any 
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  57 genomic alterations that are identified. The consent and provision of samples used for genomic 
research is separate, voluntary, and has no influence on participation in the trial.  
DNA /RNA  samples may be used for research related to tisotumab vedotin or evaluation of cervical 
cancer.  Pharmacogenomic research may consist of the analysis of one or more candidate genes or of 
the analysis of genetic markers throughout the genome in relation to tisotumab vedotin  clinical 
endpoints.  
If pharmacogenomic research evaluations  are performed, the results will be reported in a separate 
report.  
9.9 Patient Reported Outcomes  
The following health related quality of life questionnaires must be completed at the screening visit, 
on day 1 of cycle 2 and 4 and at the treatment discontinuatio n visit:  
EORTC -QLQ -C30 
The QLQ -C30 is a validated questionnaire developed by the  European Organization for Research and 
Treatment of Cancer (EORTC) to assess the quality of life of cancer patients in multicultural clinical 
research settings (Aaronson et al., 1993 ).  
EORTC -QLQ -CX24  
The EORTC -QLQ -CX24 is a validated questionnaire developed by the European Organization for 
Research and Treatment of Cancer (EORTC) to assess the quality of life in patients who are treated 
for cervical cancer both in clinical trials and i n clinical practice  (Greimel et al., 2006 ). 
Both questionnaires should  be co mpleted by the patient as first thing  upon arrival for a visit  (i.e. before 
any disease/treatment dialog with study nurse/treating physician or initiation of other preparations for 
the trial/IMP infusion).  
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  58 10 SAFETY MONITORING AN D ADVERSE EVENT REPO RTING  
10.1 Adve rse Event Definitions  
10.1.1  Definition of Adverse Events  
An adverse event (AE) is any untoward medical occurrence in a patient  whether or not considered 
related to the  medicinal product. An AE can therefore be any unfavorable and unintended sign 
(including an ab normal laboratory finding), symptom, or disease (new or exacerbated)  experienced 
by the patient.  
AEs must  be described using a diagnosis whenever possible, rather than individual underlying signs 
and symptoms. When a clear diagnosis cannot be identified, each sign or symptom must  be reported 
as a separate AE.  
10.1.2  Definition of Serious Adverse Events  
A serious ad verse event (SAE) is defined as an adverse event that meets one of the following criteria:  
 Is fatal or life -threatening1 
 Results in persistent or significant disability/incapacity  
 Constitutes a congenital anomaly/birth defect  
 Is medically significant, i.e., defined as an event that jeopardizes the patient or may require medical 
or surgical intervention to prevent one of the outcomes listed above. Medical and scientific 
judgment must be exercised in deciding whether an AE is “medically important”  
 Require s inpatient hospitalization or prolongation of existing hospitalization2  
1The term "life -threatening" in the definition of "serious" refers to an event in which the patient was 
at risk of death at the time of the event; it does not refer to an event which  hypothetically might have 
caused death if it was more severe.  
2Hospitalizations for the following reasons should not be reported as SAEs:  
 Routine treatment or monitoring of the underlying disease , not associated with any deterioration 
in condition  
 Electiv e or pre -planned treatment for a pre -existing condition that is unrelated to the indication 
under study and has not worsened since signing the informed consent  
 Social reasons and respite care in the absence of any deterioration in the patient’s general con dition  
Treatment on an emergency outpatient basis that does not result in hospital admission and involves 
an event not fulfilling any of the definitions of a n SAE given above is not a n SAE.  
10.1.3  Definition of Adverse Events of Special Interest  
Adverse events of  special interest (AESI) are defined as events (serious or non -serious) which are of 
scientific and medical concern specific to the sponsor’s product or program, for which ongoing 
monitoring and rapid communication by the investigator to the sponsor may be  appropriate. Such 
events may require further investigation in order to characterize and understand them.  
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  59 AESIs  are defined on the basis of an ongoing review of the safety data. AESIs are discussed further 
in Section 2.1.4.1  and in t he Investigator’s Brochure.  
10.1.4  Definition of Overdose of Tisotumab Vedotin  
For this trial, an overdose of tisotumab vedotin will be defined as any dose ≥ 10% of the indicated  
dose.  
10.1.5  Definition of Reproductive Potential and Contraception  
In this trial, patients are considered to have reproductive potential, UNLESS they are post -menopausal 
or permanently sterile.  
 A postmenopausal state is defined as no menses, in patients > 45 y ears of age, for 12 months 
without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the 
postmenopausal range may be used to confirm a post -menopausal state in patients  not using 
hormonal contraception or hormonal replacement  therapy. However in the absence of 12 months 
of amenorrhea, a single FSH measurement is insufficient.  
 Permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral 
oophorectomy.  
All patients must agree not to donate eggs  (ova, oocytes) for the purpose  of assisted reproduction 
during the trial and for 6 months after receiving the last dose of IMP.  
Patients of reproductive potential must agree to use adequate contraception during and for 6  months 
after the last IMP administrat ion. Adequate contraception is defined as highly effective methods of 
contraception  (Table 10-1). Birth control methods are considered highly effective  if they have a failure 
rate of less than 1% per year, when used consistently and correctly . For more information please refer 
to Appendix 1 . 
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  60 Table 10-1 Highly Effective Methods of Contraception  
 Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of 
ovulation:  
o Oral 
o Intravaginal  
o Transdermal  
 Progestogen -only hormonal contraception associated with inhibition of ovulation:  
o Oral 
o Injectable  
o Implantable1 
 Intrauterine device1 
 Intrauterine hormone -releasing system1 
 Bilateral tubal occlusion1 
 Vasectomized partner1, 2 
 Sexual abstinence3 
1 Contraception methods that in  the context of this guidance are considered to have low user dependency.  
2 Vasectomised partner is a highly effective birth control method provided that partner is the sole sexual partner 
of the woman of child -bearing potential  trial participant and that  the vasectomi zed partner has received medical 
assessment of the surgical success.  
3 In the context of this guidance sexual abstinence is considered a highly effective method only if defined as 
refraining from heterosexual intercourse during the entire pe riod of risk associated with the trial treatments. 
The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the 
preferred and usual lifestyle of the patient . 
Table adapted from ‘R ecommendations relat ed to contraception and pregnancy testing in clinical trials. Advisory non -
binding guidance represented at the CTFG -meeting in Rome 2014’ (UK MHRA., 2014 ). 
10.1.6  Definition  of Infusion Related Reactions  
An infusion related reaction is defined as an adverse events with onset during or < 24 hours after IMP 
infusion, th at is considered caused by the infusion  of tisotumab vedotin. Examples of infusion related 
reactions are: Redn ess around injection site, rash, flushing, bronchospasm, chills etc.  
 
10.2 Reporting  
Adverse Event Reporting Period:  
All AEs must be reported from the time the patients signs the ICF until 30 days after last IMP dose. 
For patients who start any new anti -cancer therapy (other than IMP) during the AE reporting period, 
only AEs that are related to IMP should be reported. Any medical condition  (signs, symptoms and 
diagnosis) occurring prior to signing the ICF, should  be recorded as medical history.   
Please note:  The intensity  of the AE , the suspected relationship to IMP treatment, action taken with 
IMP and the outcome of the AE should be  assessed a t each visit (or more frequently, if necessary). 
Instructions for reporting changes in an ongoing AE during a patient's participation in the trial are 
provided in the instructions that accompany the AE eCRF.  
 
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  61 The following Adverse  Events  must  be report ed to the Safety CRO  within 24 hours:   
 All serious adverse events (SAEs).  
 All o cular AEs, independent of grading  and seriousness . 
 All events of overdose and/or medication errors  with tisotumab vedotin , whether associated with 
an adverse event or not.   
 Any event of pregnancy . 
 
Table 10-2 Timeframes  and Documents  for Reporting of Adverse Events to the Safety CRO  
 Initial Reports  Follow -up Information on a Previous Report  
Type of 
Event  Time 
Frame  Documents  Type of 
Event  Time 
Frame  Document  
All AEs 
reportable to 
the Safety 
CRO  24 hours  Safety  Report ing 
Form  (SRF)*  All AEs 
reportable to 
the Safety 
CRO  3 days  CDS DCF  
Site DCF  
Overdose/ 
medication 
errors  24h Safety  Report ing 
Form  (SRF)*  Overdose/ 
medication 
errors  3 days  CDS DCF  
Site DCF  
Pregnancy  24 hours  Pregnancy Form  Pregnancy  3 days  CDS DCF  
* A supplemental AESI Form  must be filled in for all AESI qualifying for safety reporting. CDS=Corporate Drug Safety; 
DCF=Data Clarification Form.   
Completed Safety Reporting Forms or Pregnancy Forms must immediately be forwarded to the Safety 
CRO  
 
If you have access to a secured email you may forward c ompleted safety reporting forms or 
pregnancy forms to:  
Email:  
If you do not have access t o a secured email,  please  forward completed safety reporting forms or 
pregnancy forms to:  
Fax:  Europe: , US:  
 
Trial sites should  make every effort to respond to follow -up queries from sponsor within 3 working 
days. 

Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  62 10.2.1  Pre-existing Condition s 
In this trial, a pre -existing  condition (i.e. a disorder present before the AE reporting period has started 
and noted on the medical history form , please refer to Section 9.1.2 ) should not be reported as an AE. 
If a pre -existing condition worsens during the AE reporting period , the event must be reported as an 
AE. 
10.2.2  Diagnosis  
The diagnosis/ underlying cause of an AE  should  be recorded rather than symptoms of the AE . If no 
diagnosis is available each sign and symptom must  be recorded as individual AEs.  
10.2.3  Disease Progression  or Death  
Progression of malignancy radiologically documented by  RECIST,  should not be reported as an AE.  
However , all hospitalizations  caused by disease progression should be reported as an SAE.   
All deaths , except  death  caused by disease progression , should be reported as SAEs . 
Please note that specific clinical manifestations of disease progression (e.g., “malignant 
pleural effusion”, “spinal bone metastases”, “lymphadenopathy”, “brain metastases”) that 
meet the criteria for an SAE should be reported as the adverse event diagnosis rather than 
the unspecific term “disease progression”. If no specific clinica l symptoms meet the serious 
criteria, then it is acceptable to report “disease progression” as the diagnosis of the adverse 
event.  
10.2.4  Unrelated Procedures  
Diagnostic and therapeutic non -invasive and invasive procedures, such as surgery, should not  be 
reported  as AEs. A medical condition for which an unscheduled procedure was performed,  must  
however be reported if it meets the definition of an AE. For example, an acute  appendicitis must  be 
reported as the AE and not the appendectomy.  
10.2.5  Laboratory test abnormaliti es 
Laboratory abnormalities that induce clinical signs or symptoms, require concomitant therapy or 
require changes in trial treatment must be reported as an AE. Whenever possible, a diagnosis, rather 
than a symptom should be provided (e.g. anemia instead o f low hemoglobin). Laboratory 
abnormalities that meet the criteria for AEs must be followed until they have returned to normal or an 
adequate explanation of the abnormality is found. When an abnormal laboratory or test result 
corresponds to a sign/symptom of an already reported AE, it is not necessary to separately record the 
laboratory/test result as an additional event.  
NOTE: A CTCAE grade 3 or 4 laboratory value abnormality does not automatically indicate an SAE.  
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  63 10.2.6  Start Date and Time  
Start date for an (S) AE is the date of occurrence of the first symptom of the disease, e.g. if chest pain 
occurs on 01 April 2016 and the patient is hospitalized with myocardial infarction on 04 April 2016, 
then the onset date of the SAE myocardial infarction is 01 April 2016.  
10.2.7  Infusion -Related Reactions  (IRRs)  
For all adverse events with onset during or < 24  hours after IMP infusion, the investigator must assess 
whether the AE is considered caused by the  infusion  (please refer to Section 10.1.6  for a definition of 
IRRs ). 
10.2.8  Seriousness Criteria  
Indicate whether or not the AE is determined to be “serious” based on the criteria defined in  Section  
10.1.2 . 
10.2.9   Intensity  
The investigator will use the National Cancer Institute’s CTCAE version 5.0 to describe the intensity  
of AEs.   
Changes in intensity of an ongoing AE should be assessed  at each visit or more frequent if deemed 
necessary and should be reported in the eCRF  (please refer to the instructions that accompany the AE 
eCRF  for more information) . 
10.2.10  Relationship to the I nvestigational Medicinal Product  
The investigator must assess whether or not the event is related to treatment with tisotumab vedotin.  
The relationship is to be judged using the following terms:  
 Related  
 Not related  
“An AE related to tisotumab vedotin ” (i.e. a suspected adverse reaction) is an event for which t here 
is a reasonable possibility that the tisotumab vedotin caused the AE, meaning  there is evidence to 
suggest a causal relationship between tisotumab vedotin  and the AE. 
Please note: If the relationship changes over time, the last judgment by the investi gator should  be 
reported. Relatedness has to be assessed and reported from the first time the AE is being reported.  
10.2.11  Action Taken with the I nvestigational Medicinal Product  
The action taken with the IMP  in relation to an adverse event  must  be noted as:  
 Dose not changed  
 Dose reduced  
 Drug  interrupted  
 Drug withdrawn   
 Not applicable  
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  64 10.2.12   Outcome  
The outcome of the AE must be judged by investigator using the following terms:  
 Fatal  
 Not recovered/not resolved  
 Recovering/resolving  
 Recovered/resolved  
 Recovered  with sequelae /resolved with sequelae  
 Unknown  
10.2.13  End Date and Time 
The end date should  be filled in if the outcome of an event is fatal, recovered/resolved  or recovered 
with sequelae /resolved with sequelae.  
10.3 Events Requiring Immediate Reporting  
10.3.1  Serious Adverse Events  and Ocular Adverse Events   
 All serious AEs  must be reported to the Safety CRO  within 24h.  
 All o cular AEs, independent of grading  and seriousness , must be reported to the Safety CRO 
within 24h.  
All SAEs and  all ocular AEs  must be reported from the trial site to the sponsor no later than 24 hours 
following a) the patient visit at which such AE was reported, noted or recognized; or b) the principal 
investigator’s or any investigator personnel’s receipt of the test results or  c) other information at, or 
from which, such development was reported, noted or recognized.  
Please refer to Section 10.2 for an overview of AE repor ting timelines . 
10.3.2  Overdose and Medication Errors  
For this trial, an overdose of tisotumab vedotin will be defined as any dose ≥  10% of the indicated  
dose. All cases of overdose  with tisotumab vedotin  must be reported to sponsor  as protocol deviations 
and to the eCRF and Safety CRO  as an AE  (whether or not associated with an AE) . Reporting to the 
Safety CRO should be  completed  within 24  hours of knowledge of the event.  
Medication errors and uses outside what is foreseen in the p rotocol , including misuse and abuse of 
tisotumab vedotin , must be reported as protocol deviations to sponsor and to the eCRF and Safety 
CRO  as an AE (whether or not associated with an AE) . Reporting to the Safety CRO should be  
completed  within 24  hours of knowledge of the event.   
Rescue medication to reverse the action of tisotumab vedotin  is not available. In case of overdose, 
medication errors, misuse and/or abuse of tisotumab vedotin,  patients should  receive supportive care 
according to local guidelines and potential adverse events  should  be treated symptomatically.  
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  65 In the event of an overdose, the investigator should : 
i. Contact the sponsor’s Medical Officer immediately.  
ii. Obtain a plasma sample for PK analysis if requested by the sponsor’s Medical Officer 
(determined on a case -by-case basis).  
iii. Closely monitor the patient for any AE and laboratory abnormalities until tisotumab vedotin  
can no longer be detected systemical ly.  
10.3.3  Pregnancy  
Any pregnancy must be reported to the Safety CRO  within 24 hours of learning of its occurrence. 
Pregnant trial patients must immediately permanently discontinue IMP treatment.  The pregnancy 
should  be followed -up to determine outcome (includi ng premature termination) and status of mother 
and child. The child should  be followed at least to the age of one month. Pregnancy complications 
and elective terminations for medical reasons must be reported as an AE or SAE. Spontaneous 
abortions must be r eported as an SAE. Any SAE occurring in association with a pregnancy brought 
to the investigator’s attention after the patient has completed the trial and considered by the 
investigator as possibly related to the IMP, must be promptly reported to the Safet y CRO .  
10.4 Suspected Unexpected Serious Adverse Reactions  (SUSARs)  
The sponsor has a legal responsibility to notify, as appropriate and according to local regulations, both 
the local regulatory authority and other regulatory agencies about the safety of the p roduct under 
clinical investigation. Prompt notification of SAEs by the investigator to the sponsor is essential so 
that legal obligations and ethical responsibilities towards the safety of patients are met.  
The sponsor will ensure that all relevant inform ation about Suspected Unexpected Serious Adverse 
Reactions (SUSARs) is recorded and reported as soon as possible, but within a maximum of 15 days 
(fatal or life -threatening SUSARs within a maximum of seven days) of first knowledge by the sponsor 
or designe e, to the competent regulatory authorities and/or to the ethics committee according to the 
applicable local regulatory requirements. Relevant follow –up information of fatal or life -threatening 
SUSARs will be communicated subsequently within an additional e ight days.  
The investigator must  be aware of local reporting regulations to the IEC/IRB. The safety  CRO will 
either supply the investigator with the reports which must  be passed on to the IEC/IRB or report 
directly to the IEC/IRB, depending on local regula tions.  
10.5 Follow -Up o n Adverse Events  
All AEs must  be followed until they are resolved or until the safety follow -up visit, whichever comes 
first. However , IMP related AE SIs qualifying for safety reporting and all SAEs (independent of 
causality) still ongoing after the safety follow -up visit  should  be followed on a regular basis, according 
to the investigator’s clinical judgment, until the event has been resolved or until the investigator 
assesses it as chronic and all queries have been resolved.  
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  66 10.6 Warnings and Precautions  
No evidence available at the time of the approval of this trial protocol indicated that special warnings 
or precautions were appropriate, other than those noted in the provided Investigator’s Brochure. 
Additional safety information  collected between Investigator’s Brochure  updates will be 
communicated in the form of investigator notifications. This information will be included in the 
patient  informed consent and must  be discussed with the patient  during the trial as needed.  
10.7 Data Mon itoring Committee  
This trial will institute a data monitoring committee (DMC), which will function independently of all 
other individuals associated with the conduct of this clinical trial, including the trial site  investigators 
participating in the trial.  The DMC will consist at a minimum of two physicians with appropriate 
disease area qualifications and, where applicable, a statistician.  The functions and responsibilities of 
the DMC will be described in the DMC Charter, which will be approved by the DMC.  During the trial 
the DMC may meet at regular intervals or ad hoc, as defined in the DMC charter.  
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  67 11 STATISTICS  
The Statistical Analysis Plan (SAP) will be developed and finalized before database lock. This section 
is a summary of the planned statistical analyses of the primary and secondary endpoints.  
The primary analysis  of the trial will be based on a data cutoff approximately 6 months after all 
responders  have experienced their first response as assessed by the investigator  per RECIST v1.1 . 
All data will be listed. Baseline is defined as the latest available measurement made before the first 
treatment with tisotumab vedotin.  
11.1 Analysis Sets 
11.1.1  Full Analysis Set 
The full analysis set (FAS) comprises all patient s who received at least one dose of trial treat ment. 
11.1.2  Safety Set 
The safety set includes all patient s who received at least one dose of trial treatment ; thus, the full 
analysis set and the safety set is identical . 
11.2 Patient  Demographics and Baseline Characteristics  
Demographic and other baseline data including disease characteristics w ill be listed and summarized 
descriptively for the safety set .  
Categorical data will be presented as frequencies and percentages. For continuous data, mean, 
standard deviation, median, minimum, and maximum will be presen ted. 
Relevant medical histories and current medical history at baseline will be summarized separately  by 
system organ class and preferred term.  
11.3 Treatments  
The safety set will be used for the analyses below. Categorical data will be summarized as frequencie s 
and percentages. For continuous data, mean, standard deviation, median, 25th and 75th percentiles, 
minimum, and maximum will be presented.  
The duration of exposure in months  to tisotumab vedotin  as well as the dose intensity (computed as 
the ratio of ac tual cumulative dose received and actual duration of exposure) will be summarized by 
means of descriptive statistics using the safety set.  
The number of patient s with dose adjustments ( delay, reductions  or permanent discontinuation) and 
the reasons will b e summarized and all dosing data will be listed.  
Concomitant medications and significant non -drug therapies prior to and after the start of the trial 
treatment will be listed and summarized according to the anatomical therapeutic chemical (ATC) 
classificat ion system.  
11.4 Primary Objective  
Determine the anti-tumor efficacy  in patient s with cervical cancer.   
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  68 11.4.1  Endpoint  
 Confirmed objective response rate (ORR) based upon RECIST v1.1, assessed by the independent 
review committee (IRC).  
Confirmed O RR is defined (based on IRC verified CT scan results) as a best overall response (PR or 
better) confirmed by a subsequent best overall response of PR or better at least four weeks later.  
11.4.2  Statistical Hypothesis, Model and Method of Analysis  
The following statistical hypotheses will be tested to address the primary efficacy objective:  
𝐻0: 𝜃≤11%    𝑣𝑠.   𝐻𝐴: 𝜃>11%  
where θ is the objective response rate. The test will be performed as an exact test at a one -sided 2.5% 
alpha level.  
In addition an exact 95 % two -sided confidence interval for the objective response rate will be provided  
using the Clopper -Pearson method . 
The analysis will be performed on the FAS with an ITT approach so that any patient s with missing 
information regarding response to treatment will be counted as non -responders.  
11.4.3  Handling of Missing Values/ Censoring/ Discontinuations  
Any patient s with missing information regarding response to treatment  will be counted as non -
responders.  
11.4.4  Supportive and Sensitivity Analyses  
ORR  including unconfirmed responders will also be analy zed as a supportive analysis.  
Subgroup analyses will be provided by histology  (adenocarcinoma, adeno -squamous and squamous 
cell carcino ma), prior radiation for localized disease (Y /N), bevacizumab (Y/N) , prior lines of therapy , 
response to last therapy (Y/N)  and by TF expression in biopsy as measured by IHC  (details to be 
specified in the SAP ). 
Because of the lower expected number of patients per center, no center effect will be investigated, but 
subgroup  analyses by region (EU/US) will be done to assess regional consistency of treatment effects.  
Further confirmed ORR,  as assessed by the investigator , will be analyzed and summarized in the same 
way.  
11.5 Secondary Objectives  
11.5.1  Secondary Efficacy Objectives  
 Evalua te tumor response durability . 
 Evaluate clinical response . 
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  69 11.5.1.1  Secondary Efficacy Endpoints  
Duration of response (DOR) based upon RECIST v1.1, assessed by the IRC   
Duration of response ( DOR ) only applies to the subset of patient s in the FAS whose best overall 
response is CR or PR according to RECIST v1.1  (Eisenhauer et al., 2009 ), based on tumor response 
data per IRC review. The start date is the date of first documented response of CR or PR (i.e. the start 
date of response, not the date when response was confirmed), and the end date is defined as the date 
of the first documented disease progression verified by IRC or death. Patient s continuing without 
disease progression or death will be censored and t he censori ng date will be the date of the last 
adequate tumor assessment prior to data cut-off/start of new anti-cancer  therapy. The data cut -off is 
the date defining the data to be included in the analysis. All data up to and including this date will be 
included. In case of progression after >2 missed visits, censoring will be done at last adequate tumor 
assessment date. DOR will be listed and summarized for all patient s in the FAS with confirmed best 
overall response of CR or PR.  
DOR  distribution will be estimated using the Kaplan -Meier method, and the survival  curve, median 
and 95% confidence interval o f the median will be presented.  
Confirmed ORR based upon RECIST v1.1, assessed by the investigator   
Investigator assessed confirmed ORR will be analyzed as described  for the primary endpoint.  
DOR based upon RECIST v1.1, assessed by the investigator   
Investigator  assessed DOR will be analyzed as described for IRC assessed DOR.  
Time to response (TTR) based upon RECIST v1.1, assessed by the IRC and by the investigator  
Time to response ( TTR ), whether assessed by IRC or investigator,  is defined as the time from the date 
of the first IMP administration  to the first documented response of either CR or PR, which must be 
subsequently verified by the IRC  (although date of init ial response is used, not date of confirmation). 
CR and PR are based on tumor response data as per blinded independent central review and according 
to RECIST 1.1 (Eisenhauer et al., 2009 ). 
All patient s in t he FAS will be included in TTR calculations. Patients without a confirmed CR or PR 
will be censored and the censoring date will be the date of the last adequate tumor assessment prior to 
cut-off/start of new anti -cancer therapy.  TTR will be listed and summ arized.  
Progression free survival (PFS) based upon RECIST v1.1, assessed by the IRC and by the 
investigator  
Progression free survival ( PFS) is defined as the time from the date of the first IMP administration  to 
the date of the first documented disease progression or death due to any cause. PFS will be assessed 
via blinded independent central  review according to RECIST 1.1 (Eisenhauer et al., 2009 ). PFS will 
be censored if no PFS event is observed before the first to occur between: (i) the analysis cut -off date, 
and (ii) the date when a new anti-cancer  therapy is started. The censoring date will be the date of the 
last adequate tumor assessment prior to cut -off/start of new anti-cancer  therapy.  In case of progression 
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  70 after >2 missed visits, censoring will be done at last adequate tumor assessment date  prior to the 
missed visits . 
PFS will be analyzed in the FAS populat ion. The PFS distribution will be estimated using the Kaplan -
Meier method, and the Kaplan -Meier curve, median and 95% confidence interval of the median will 
be presented.  
Six and 12 months PFS rates (i.e. percentage of patient s with PFS ≥ 6 months and ≥ 12 months 
respectively) will be summarized.  
Overall Survival  (OS)  
Overall survival  is defined as the time from the date of the first IMP administration  to the date of 
death due to any cause. If a patient  is not known to have died, then OS will be censored and the 
censoring date will be  the latest date the patient  was known to be alive (on or before the cut -off date).  
OS will be analyzed in the FAS population. The OS distribution will be estimated using the Kaplan -
Meier method, and the Kaplan -Meier curve, median, first and third quartiles and 95% confidence 
interval of the median will be presented . 
Six and 12 months OS rates (i.e. percentage of patient s with OS ≥ 6 months and ≥ 12 months 
respectively) will be summarized.  
11.5.1.2  Supportive Analyses of Secondary Eff icacy Objectives and Endpoints  
Subgroup analyses will be provided as for the primary endpoint (Section 11.4.4 ). 
11.5.2  Safety Objectives  
The secondary safet y objective is : 
 Assess safety and tolerability.  
11.5.2.1  Analysis Set and Grouping for the Analyses  
For all safety analyses, the safety set will be used.  
The overall observation period will be divided into three  mutually exclusive segments:  
1. Pre-treatment period: from day of patient ’s informed consent to the day before first IMP 
administration . 
2. On-treatment period: from day of first dos e of trial medication to 30 days after last IMP 
administration . 
3. Post-treatment: From 31 days after last IMP a dministration.  
11.5.2.2  Adverse Events  
Summary tables for AEs will include only AEs that started or worsened during the on -treatment 
period, the treatment -emergent AEs.  
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  71 The incidence of treatment -emergent AEs (new or worsening from baseline) will be summarized by 
system organ class and or preferred term, severity (based on CTCAE version  5.0 grades ), type of AE 
and relationship to trial treatment  
SAEs, non -serious AEs , AEs leading to withdrawal  and AEs of special interest (AESI) during the on -
treatment period will be tabulated.  
All deaths (on -treatment and post -treatment) will be summarized.  
All AEs, deaths and SAEs (including those from the pre and post -treatment periods) will be listed and 
those collected during the pre -treatment and post -treatment period will b e flagged.  
Further summaries of AEs , including summaries of AESIs  will be specified in the statistical analysis 
plan.  
11.5.2.3  Laboratory Abnormalities  
Grading of laboratory values will be assigned programmatically as per the National Cancer Institute’s 
CTCAE versi on 5.0. The calculation of CTCAE grades will be based on the observed laboratory 
values only, clinical assessments will not be taken into account.  
CTCAE grade 0 will be assigned for all non -missing values not graded as 1 or higher.  
For laboratory tests whe re grades are not defined by the CTCAE, results will be categorized as 
low/normal/high based on laboratory normal ranges.  
The following summaries will be generated separately for hematology and biochemistry tests:  
 Listing of all laboratory data with values  flagged to show the corresponding CTCAE grades, if 
applicable, and the classifications relative to the laboratory normal ranges.  
 For continuous variables  for both the raw value and change from baseline : 
o Summary tables by visit with mean, st andard deviation (SD) , median, min and max. The tables 
should include summaries of the last value as well as of the highest and the lowest value . 
o Box plots by visit . 
 For categorical variables : 
o Summary tables with frequencies of each response .  
 For laboratory tests  where grades are defined by the CTCAE:  
o Worst post -baseline CTCAE grade (regardless of the baseline status). Each patient  will be 
counted only once for the worst grade observed post -baseline.  
o Shift tables using CTCAE grades to compare baseline to the worst  on-treatment value.  
 For laboratory tests where grades are not defined by the CTCAE:  
o Shift tables using the low/normal/high/ (low and high) (or other project -specific) classification 
to compare baseline to the worst on -treatment value.  
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  72 11.5.2.4  Other Safety Data 
ECG 
12-lead ECGs including PR, QRS, QT, QTcF, and RR intervals will be obtained for each patient  
during the trial. ECG data will be read and interpreted centrally.  
Categorical analysis of QT/QTc interval data based on the number of patient s meeting or excee ding 
predefined limits in terms of absolute QT/QTc intervals or changes from baseline will be presented. 
In addition, a listing of these patient s will be produced.  
Vital Signs 
Data on vital signs will be tabulated and listed; notable values will be flagged . 
Immunogenicity (anti -drug antibodies) of tisotumab vedotin:  
Data on immunogenicity will be tabulated and listed; notable values will be flagged.  
11.5.3  Pharmacokinetics  
The plasma concentrations will be summarized by sampling time points , listed  and presented 
graphically . Values below limit of quantification will be counted as having a value of half the lower 
limit of quantification.  
11.5.3.1  Data Handling Principles  
Missing concentration values will be reported as is in data listings. Concentration values below the 
lower limit of quantitation will be handled as LLOQ/2  in summary statistics, and reported as is in data 
listings. Any missing concentration data will not be imputed.  
11.5.4  Biomarkers  
The biomarker assessments are intended to evaluate potential pharmacodynamic markers, and to 
identify markers predictive of response or resistance to tisotumab vedotin. Since this clinical trial is 
not designed to address specific biomarkers -related statis tical hypotheses, the analysis of these data 
should be viewed as exploratory and hypotheses generating.  
Biomarkers, including disease progression  markers, may be listed, tabulated, and plotted when 
deemed appropriate.  Analyses will be stratified by clinic al covariates or molecular subgroups using 
the appropriate statistical methods (e .g., parametric or non -parametric, univariate or multivariate, 
analysis of variance, or survival analysis) depending on the endpoint and the hypotheses. Baseline  
biomarker lev els, or changes in biomarker levels, will be assessed for correlation with response and 
other clinical endpoints to identify responsive or resistant subgroups, as well as biomarkers or 
pathways attenuated following tr eatment with tisotu mab vedotin.   
Addit ional analyses that may be performed after the completion of the end -of-trial clinical trial report  
and will be documented in separate reports. These analyses may include , but are not limited to , the 
meta -analysis of data from this trial combined with data  from other trials or the analysis of biomarkers 
generated from samples collected during the trial but analyzed after the database lock and completion 
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  73 of the clinical trial report . The data analysis will be described in an addendum of the statistical analy sis 
plan or in a stand -alone analysis plan document, as appropriate.  
Planned analyses are based on the availability of clinically valid assays and may be deferred if 
emerging trial data shows no likelihood of providing useful scientific information.  
11.5.5  Resour ce Utilization  
Not applicable.  
11.5.6  Patient -reported  Outcomes  
Endpoints on patient -reported outcomes will be summarized and listed.  
11.6 Exploratory Objectives  
 Assess biomarkers related to clinical response.  
 Assess potential pharmacodynamic biomarkers.  
 Assess Health  Related Quality of Life (HRQL).  
Please see Section 11.5.4  for a high level description of the planned biomarker analyses. Further 
details on those analyses and  the summary of the HRQL measures will be described in the Statistical 
Analysis Plan . 
11.7 Interim Analyses  
No formal interim analyses are planned. The primary analy sis of the trial will be based on a data cutoff 
approximately 6 months after all responders  have experienced their first response as assessed by the 
investigator  per RECIST v1.1 . 
Since patient s will be treated until disease progression or withdrawal some patient s may be still be 
ongoing at that time  point and in that case the entire tr ial will be reported again when the last patient  
completes the trial.   
11.8 Sample Size Calculation  
In GEN701 there were 9 confirmed responders among the first 34 cervical cancer patients (26%).  
Applying a one -sided exact binomial test at the 0.025 significan ce level, the planned sample size of 
100 patients provides ≥80% power to reject an ORR of 11%, the combined ORR for available second -
line therapies (Section 2.2), or less for true ORRs in the range 21% - 25%, representing clinically 
relevant improvements over available second -line treatments ( Table 11-1).  
Table 11-1 Power for a range of clinically relevant true confirmed ORRs  
True ORR  21% 22% 23% 24% 25% 
Power  80% 86 91% 94% 96% 
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  75 The following data may be recorded directly into the eCRF and could be  considered source data:  
 Race  and ethnicity . 
12.3 Case Report Form Completion  
Case report forms are provided for each patient  in electronic format.  
Electronic data capture ( EDC) will be used for this trial. The trial data will be transcribed by trial site  
personnel from the source documents onto an electronic CRF, and transmitted in a secure manner to 
the sponsor within the timeframe agreed upon between the sponsor and the trial site. The electronic 
file will be considered to be the CRF.  
Worksheets may be used for the capture of some data to facilitate completion of the eCRF. Any such 
worksheets will become part of the patient 's source documentation. All data relating to the trial must 
be recorded in eCRFs prepared by the sponsor. Data must be entered into eCRFs in English. Trial site 
personnel should make every effort to  enter data into the  eCRF no later than 5 working days after 
granted trial enrollment and/or  after each patient  visit.  
The investigator must verify that all data entries in the eCRFs are acc urate and correct.  
All eCRF entries, corrections, and alterations must be made by the investigator or other authorized 
trial site  personnel. If necessary, queries will be generated in the EDC tool.  
If corrections to an eCRF are needed after the initial ent ry into the eCRF, this can be done in three 
different ways:  
 Trial site personnel can make corrections in the EDC tool at their own initiative or as a response 
to an auto query (generated by the EDC tool).  
 The monitor  can generate a query for resolution by the trial site  personnel.  
 The clinical data manager can generate a query for resolution by the trial site  personnel.  
 The spo nsor can generate a query for resolution by the trial site  personnel.  
12.4 Data Quality Management  
Steps to be taken to ensure the accura cy and reliability of data include the selection of qualified 
investigators and appropriate trial sites, review of protocol procedures with the investigator and trial 
site personnel before the trial,  and periodic monitoring visits by the sponsor and direct  transmission 
of clinical laboratory data from a central laboratory , ECG and scan data from a central imaging vendor  
into the sponsor's data base. Written instructions will be provided for collection, handling, storage, 
and shipment of samples.   
Guidelines  for eCRF completion will be provided and reviewed with trial site  personnel before the 
start of the trial. The sponsor will review eCRFs for accuracy and completeness during on -site 
monitoring visits and after transmission to the sponsor; any discrepancie s will be resolved with the 
investigator or designee, as appropriate. After upload of the data into the trial database they will be 
verified for accuracy and consistency with the data sources.  
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  76 12.5 Record Retention  
In compliance with the ICH/GCP guidelines, the investigator/institution will maintain all eCRFs and 
all source documents, as well as a source document location list, that support the data collected from 
each patient , as well as all trial documents as speci fied in ICH/GCP  (R2) guideline Section 8, Essential 
Documents for the Conduct of a Clinical Trial (ICH, 2016 ), and all trial documents as specified by 
the ap plicable regulatory requirements . The investigator /institut ion will take measures to prevent 
accidental or premature destruction of these documents.  
Essential documents must be retained for 25 years after end of trial.  These documents will be retained 
for a longer period if required by the applicable regulatory re quirements or by an agreement with the 
sponsor. It is the responsibility of the sponsor to inform the investigator/institution as to when these 
documents no longer need to be retained.  
If the responsible investigator retires, relocates, or for other reason s withdraws from the responsibility 
of keeping the trial records, custody must be transferred to a person who will accept the responsibility. 
The sponsor must be notified in writing of the name and address of the new custodian. Under no 
circumstance shall the investigator relocate or dispose of any trial documents before having obtained 
written approval from the sponsor.  
If it becomes necessary for the sponsor or the appropriate regulatory authority to review any 
documentation relating to this trial, the in vestigator/institution must permit access to such reports.  
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  77 13 ETHICS  
13.1 Trial -Specific Design Considerations  
Potential patient s will be fully informed of the risks and requirements of the trial and, during the trial, 
patient s will be given any new information that may affect their decision to continue participation. 
Only patient s who are fully able to understand the risks, benefits, and potential AEs of the trial, and 
provide their consent voluntarily will be enrolled.  
The to tal blood volume to be collected is considered to be within the normal range allowed for this 
patient  population over the time frame  of the trial . 
13.2 Regulatory Ethics Compliance  
13.2.1  Investigator Responsibilities  
The investigator is responsible for ensuring that the trial is performed in accordance with the protocol, 
ICH GCP  E6 (R2) , and applicable regulatory and country -specific requirements  (ICH, 2016 ). 
GCP is an international ethical and scientific quality standard for designing, conducting, recording, 
and reporting trials that involve the participation of human subjects. Compliance with this standard 
provides public assurance that the rights, safety, an d well -being of trial subject s are protected, 
consistent with the principles that originated in the Declaration of Helsinki  (The World Medical 
Association, 2013 ), and that the tria l data are credible.  
13.2.2  Independent Ethics Committee or Institutional Review Board  
This trial will be undertaken only after the IEC/IRB has given full approval of the final protocol, 
amendments (if any, excluding the ones that are purely administrative, with no consequences for 
patient s, data or trial conduct), the ICF, applicable recruiting materials, and patient  compensation 
programs, and the sponsor has received a copy of this approval. This approval letter must be dated 
and must clearly identify the IEC/IR B and the documents being approved.  
Approval for the collection of optional samples for research and for the corresponding ICF must be 
obtained from the IEC/IRB. Approval for the protocol can be obtained independent of this optional 
research component.  
For all protocol amendments (excluding the ones that are purely administrative, with no consequences 
for patient s, data or trial conduct), the amendment and applicable ICF revisions must be submitted 
promptly to the IEC/IRB for review and approval before imp lementation of the change(s).  
Where applicable, interim reports on the trial and/or reviews of trial progress will be submitted by the 
investigator to the IEC/IRB at intervals stipulated in the IEC/IRB guidelines.  
At the end of the trial, the investigator  (or sponsor where required) will notify the IEC/IRB about the 
trial completion.  
13.2.3  Informed Consent  
Each patient  must give written consent according to local requirements after the nature of the trial ha s 
been fully explained. The ICFs  must be signed before performance of any trial -related activity. The 
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  78 ICF that is used must be approved by both the sponsor and by the reviewing IEC/IRB and be in a 
language that the patient  can read and understand. The informed consent must  be in accordance with 
principles that  originated in the Declaration of Helsinki, current ICH GCP E6(R2) guidelines, 
applicable regulatory requirements, and sponsor policy.  
Before enrollment in the trial, the investigator or an authorized member of the trial site  personnel must 
explain to potential patient s the aims, methods, reasonably anticipated benefits, and potential hazards 
of the trial, and any discomfort participation in the trial may entail. Patient s will be informed that their 
participation is voluntary and that they may withdraw consent to participate at any time. They will be 
informed that choosing not to participate will not affect the care that the patient  will receive for the 
treatment of his or her disease . Patient s will be told that alternative tre atments are available if they 
refuse to take part and that such refusal will not prejudice future treatment.  Finally, they will be told 
that the investigator will maintain a patient  identification register for the purposes of long -term follow -
up if needed and that their records may be accessed by health authorities and authorized sponsor 
personnel without violating the confidentiality of the patient , to the extent permitted by the applicable 
law(s) or regulations. By signing the ICF the patient  is authorizi ng such access, including permission 
to obtain information about his or her survival status,  and agrees to allow his or her trial physician to 
recontact the patient  for the purpose of obtaining consent for additional safety evaluations, if needed , 
and subs equent disease -related treatments, or to obtain information about his or her survival status . 
The patient  will be given sufficient time to read the ICF and the opportunity to ask questions. After 
this explanation and before entry into the trial, consent must be appropriately recorded by means of 
the patient 's personally dated signature. After having obtained the consent, a copy of the ICF must be 
given to the patient . 
Patients  will be asked for consent to provide optional samples for research  where local re gulations 
permit . After informed consent for the trial is appropriately obtained, the patient  will be asked to sign 
and personally date a separate ICF indicating agreement to participate in the optional research 
component  (Section 13.2.5 ). Refusal to participate in the optional research will not result in 
ineligibility for the trial. A copy of this signed ICF will be given to the patient . 
13.2.4  Privacy of Personal Data 
The collection and processing of personal data from patients enrolled in this trial will be limited to 
those data that are necessary to fulfill the objectives and purposes of the trial.  
These data must be collected and processed with adequate precautions to ensure confidentiality and 
compliance with applicable data privacy protection laws and regulations. Appropriate technical and 
organizational measures to protect the personal data against unauthorized disclosures or access, 
accidental or unla wful destruction, or accidental loss or alteration must be put in place. Sponsor 
personnel whose responsibilities require access to personal data agree to keep the identity of patient s 
confidential.  
The informed consent obtained from the patient  includes e xplicit consent for the processing of 
personal data for the purpose of the trial and for the investigator/institution to allow direct access to 
his or her original medical records (source data/documents) for trial -related monitoring, audit, 
IEC/IRB review,  and regulatory inspection. This consent also addresses the transfer of the data to 
other entities and to other countries.  
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  79 The patient has the right to request through the investigator access to his or her personal data and the 
right to request rectificati on of any data that are not correct or complete. Reasonable steps will be 
taken by the investigator to respond to such a request, taking into consideration the nature of the 
request, the conditions of the trial, the clinical trial agreement including the d ata processor agreement 
and applicable laws and regulations. The investigator will inform - and work together with the sponsor 
when handling such requests.  
Exploratory DNA , biomarker , PK and immunogenicity research is not conducted under standards 
appropria te for the return of data to patient s. In addition, the sponsor cannot make decisions as to the 
significance of any findings resulting from exploratory research. Therefore, exploratory research data 
will not be returned to patient s or investigators, unless  required by law or local regulations. Privacy 
and confidentiality of data generated in the future on stored samples will be protected by the same 
standards applicable to all other clinical data.  
13.2.5  Long -term Retention of Samples  
If it is determined at any t ime before trial completion that additional material is needed from a FFPE 
tumor sample for the successful completion of the protocol -specified analyses, the Sponsor may 
request that additional material be retrieved from existing samples. Also, based on em erging scientific 
evidence relating to a potential correlation between a biomarker and treatment efficacy an d/or safety 
the s ponsor may request additional material from previously collected tumor samples during the 
clinical trial or for a period of 5  years  after trial completion for a retrospective analysis. In this case, 
such analyses would be specific to research related to the IMP or diseases being investigated in the 
clinical trial.  
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  80 14 ADMINISTRATIVE PROCE DURES  
14.1 Protocol Amendments  
Neither the investigator nor the sponsor will modify this protocol without a formal amendment by the 
sponsor. All protocol amendments must be issued by the sponsor, and signed and dated by the 
investigator. Protocol amendments must not be implemented without prior IEC/IRB approval , or when 
the relevant competent authority has raised any grounds for non -acceptance, except when necessary 
to eliminate immediate hazards to the patients, in which case the amendment must be promptly 
submitted to the IEC/IRB and relevant competent authori ty. Documentation of amendment approval 
by the investigator and IEC/IRB must be provided to the sponsor. When the change(s) involves only 
logistic or administrative aspects of the trial, the IRB (and IEC where required) only needs to be 
notified.  
During th e course of the trial, in situations where a departure from the protocol is unavoidable, the 
investigator or other physician in attendance will contact the appropriate sponsor representative (see 
contact information page(s) provided separately). Except in emergency situations, this contact must  
be made before implementing any departure from the protocol. In all cases, contact with the sponsor 
must be made as soon as possible to discuss the situation and agree on an appropriate course of action. 
The data rec orded in the eCRF and source documents will reflect any departure from the protocol, 
and the source documents will describe this departure and the circumstances requiring it.  
14.2 Regulatory Documentation  
14.2.1  Regulatory Approval/ Notification  
This protocol and any amendment(s) must be submitted to the appropriate regulatory authorities in 
each respective country, if applicable. A trial may not be initiated until all local regulatory 
requirements are met.  
14.3 Patient  Identification, Enrollment, and Screening Logs  
The inv estigator agrees to complete a patient  identification and enrollment log to permit easy 
identification of each patient  during and after the trial. This document will be reviewed by the sponsor 
trial site  contact for completeness.  
The patient identification  and enrollment log will be treated as confidential and will be filed by the 
investigator in the Investigator Site file and will never be transferred to the Sponsor or any third 
parties . To ensure patient confidentiality, no copy will be made. All reports and communications 
relating to the trial will identify patients by their patient number (or screening number if not enrolled).  
The investigator must also complete a patient  screening log, which reports on all patient s who were 
seen to determine eligibility  for inclusion in the trial. 
14.4 Monitoring  
The sponsor will use a combination of monitoring techniques remote and on -site monitoring  to 
monitor this trial.  
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  81 The sponsor will perform on -site monitoring visits as frequently as necessary. The monitor will record 
dates of the visits in a trial site visit log that will be kept at the trial site. The first post -initiation 
monitoring visit will be performed  shortly  after the first patient  has been enrolled . At these visits, the 
monitor will compare data entered into the eCRFs with the hospital or clinic records (source 
documents ). The nature and location of all source documents will be identified to ensure that all source 
of original data required to complete the eCRFs are known to the sponsor and trial site  personnel and 
are accessible for verification by the sponsor trial site  contact. If electronic records are maintained at 
the trial site, the method of verification and monitor access must be discussed with the trial site  
personnel.  
Direct access to source documentation (medical records) must be allowed for the purpose of verifyi ng 
that the data recorded in the eCRF are consistent with the original source data. Findings from this 
review of eCRFs and source documents will be discussed with the trial site  personnel. The sponsor 
expects that, during monitoring visits, the relevant trial site  personnel will be available, the source 
documentation will be accessible, and a suitable environment will be provided for review of trial -
related documents. The monitor will meet with the investigator on a regular basis during the trial to 
provide  feedback on the trial conduct.  
In addition to on -site monitoring visits, remote contacts will occur. It is expected that during these 
remote contacts, trial site  personnel will be available to provide an update on the progress of the trial 
at the trial si te.  
Central monitoring will take place for data identified by the sponsor as requiring central review.  
14.5 On-Site Audits  
Representatives of the sponsor's clinical quality assurance department may visit the trial site at any 
time during or after completion of  the trial to conduct an audit of the trial in compliance with 
regulatory guidelines and company policy. These audits will require access to all trial records, 
including source documents, for inspection and comparison with the eCRFs. Patient  privacy must, 
however, be respected. The investigator and trial site  personnel are responsible for being present and 
available for consultation during routinely scheduled trial site  audit visits conducted by the sponsor 
or its designees.  
Similar auditing procedures may  also be conducted by agents of any regulatory body, either as part of 
a national GCP compliance program or to review the results of this trial in support of a regulatory 
submission. The investigator must  immediately notify the sponsor if he or she has bee n contacted by 
a regulatory agency concerning an upcoming inspection.  
14.6 Publication  
All information, including but not limited to information regarding tisotumab vedotin  or the sponsor's 
operations (e.g. patent application, formulas, manufacturing processes,  basic scientific data, prior 
clinical data, formulation information) supplied by the sponsor to the investigator and not previously 
published, and any data, including pharmacogenomic or biomarker resea rch data, generated as a result 
of this trial, are con sidered confidential and remain the sole property of the sponsor. The investigator 
agrees to maintain this information in confidence and use this information only to accomplish this 
trial, and will not use it for other purposes without the sponsor's prior written consent.  
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  82 The investigator understands that the information developed in the trial will be used by the sponsor in 
connection with the continued development of tisotumab vedotin , and thus may be disclosed as 
required to other clinical investigators o r regulatory agencies. To permit the information derived from 
the clinical trials to be used, the investigator is obligated to provide the sponsor with all data obtained 
in the trial.  
The results of the trial will be reported in a CTR generated by the spon sor and will contain eCRF data 
from all trial sites that participated in the trial. Recruitment performance or specific expertise related 
to the nature and the key assessment parameters of the trial will be used to determine a coordinating 
investigator. Re sults of pharmacogenomic or biomarker analyses performed after the CTR has been 
issued will be reported in a separate report and will not require a revision of the CTR. Trial patient 
identifiers will not be used in publication of results. Any work created in connection with performance 
of the trial and contained in the data that can benefit from copyright protection (except any publication 
by the investigator as provided for below) shall be the property of the sponsor as author and owner of 
copyright in suc h work.  
Consistent with Good Publication Practices and International Committee of Medical Journal Editors 
guidelines, the sponsor in conjunction with any collaborative group(s) shall have the right to publish 
such primary (multicenter) data and information  as per the pre-specified and approved publication 
plan. If an investigator wishes to publish information from the trial, a copy of the manuscript must be 
provided to the sponsor for review at least 60 days before submission for publication or presentation . 
Expedited reviews will be arranged for abstracts, poster presentations, or other materials. If requested 
by the sponsor in writing, the investigator will withhold such publication  for up to an additional 60 
days to allow for filing of a patent applicatio n. In the event that issues arise regarding scientific 
integrity or regulatory compliance, the sponsor will review these issues with the investigator. The 
sponsor will not mandate modifications to scientific content and does not have the right to suppress 
information. For multicenter trial designs and sub -trial approaches, secondary results generally should 
not be published before the primary endpoints of a trial have been published. Similarly, investigators 
will recognize the integrity of a multicenter tri al by not submitting for publication data derived from 
the individual trial site until the combined results from the completed trial have been submitted for 
publication, within 12 months of the availability of the final data (tables, listings, graphs), or the 
sponsor confirms there will be no multicenter trial publication.  
Authorship of abstracts and publications resulting from this trial will be based on ICMJE guidelines, 
patient recruitment efforts and standard operating procedures of the sponsor.  
 
Regis tration of Clinical Trials and Disclosure of Results  
The sponsor will register and/or disclose the existence of and the results of clinical trials as required 
by law.    
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  83 15 REFERENCES  
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J. et al. (1993). The 
European Organization for Research and Treatment of Cancer QLQ -C30: a quality -of-life 
instrument for use in international clinical trials in oncology. J.Nat l.Cancer Inst., 85, 365 -376. 
American Cancer Society (2017). Cancer Facts & Figures.  
Burotto, M., Edgerly, M., Poruchynsky, M., Velarde, M., Wilkerson, J., Kotz, H. et al. (2015). Phase 
II Clinical Trial of Ixabepilone in Metastatic Cervical Carcinoma. Onc ologist., 20, 725 -726. 
Candelaria, M., Arias -Bonfill, D., Chavez -Blanco, A., Chanona, J., Cantu, D., Perez, C. et al. (2009). 
Lack in efficacy for imatinib mesylate as second -line treatment of recurrent or metastatic 
cervical cancer expressing platelet -derived growth factor receptor alpha. Int.J Gynecol.Cancer, 
19, 1632 -1637.  
Coronel, J., Cetina, L., Candelaria, M., Gonzalez -Fierro, A., Arias, D., Cantu, D. et al. (2009). Weekly 
topotecan as second - or third -line treatment in patients with recurrent or meta static cervical 
cancer. Med.Oncol, 26, 210 -214. 
Doronina, S. O., Toki, B. E., Torgov, M. Y., Mendelsohn, B. A., Cerveny, C. G., Chace, D. F. et al. 
(2003). Development of potent monoclonal antibody auristatin conjugates for cancer therapy. 
Nat.Biotechnol.,  21, 778 -784. 
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R. et al. (2009). New 
response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur.J 
Cancer, 45, 228 -247. 
FDA (2016). Drug Develo pment and Drug Interactions: Table of Substrates, Inhibitors and Inducers . 
Available from: 
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInte
ractionsLabeling/ucm093664.htm , accessed on 15/September/2017 . 
Ferlay, J., Soerjoma taram, I., Ervik, M., Dikshit, R., Eser, S., Mathers, C. et al. (2012). GLOBOCAN 
2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. 
Lyon, France: International Agency for Research on Cancer; 2013. Available from: 
http:/ /globocan.iarc.fr, accessed on 12/ October/2017.  
Fiorica, J. V., Blessing, J. A., Puneky, L. V., Secord, A. A., Hoffman, J. S., Yamada, S. D. et al. 
(2009). A Phase II evaluation of weekly topotecan as a single agent second line therapy in 
persistent or rec urrent carcinoma of the cervix: a Gynecologic Oncology Group study. 
Gynecol.Oncol, 115, 285 -289. 
Garcia, A. A., Blessing, J. A., Vaccarello, L., & Roman, L. D. (2007). Phase II clinical trial of 
docetaxel in refractory squamous cell carcinoma of the cervix : a Gynecologic Oncology Group 
Study. Am.J Clin Oncol, 30, 428 -431. 
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  84 Goncalves, A., Fabbro, M., Lhomme, C., Gladieff, L., Extra, J. M., Floquet, A. et al. (2008). A phase 
II trial to evaluate gefitinib as second - or third -line treatment in patients with rec urring 
locoregionally advanced or metastatic cervical cancer. Gynecol.Oncol, 108, 42 -46. 
Greimel, E. R., Kuljanic, V. K., Waldenstrom, A. C., Duric, V. M., Jensen, P. T., Singer, S. et al. 
(2006). The European Organization for Research and Treatment of Can cer (EORTC) Quality -
of-Life questionnaire cervical cancer module: EORTC QLQ -CX24. Cancer, 107, 1812 -1822.  
Hamblett, K. J., Senter, P. D., Chace, D. F., Sun, M. M., Lenox, J., Cerveny, C. G. et al. (2004). 
Effects of drug loading on the antitumor activity o f a monoclonal antibody drug conjugate. 
Clin.Cancer Res., 10, 7063 -7070.  
Homesley, H. D., Meltzer, N. P., Nieves, L., Vaccarello, L., Lowendowski, G. S., & Elbendary, A. A. 
(2008). A phase II trial of weekly 1 -hour paclitaxel as second -line therapy for end ometrial and 
cervical cancer. Int.J Clin Oncol, 13, 62 -65. 
ICH (2016). Integrated addendum to ICH E6(R1): Guideline for good clinical practice E6(R2).  
McLachlan, J., Boussios, S., Okines, A., Glaessgen, D., Bodlar, S., Kalaitzaki, R. et al. (2017). The 
Impact of Systemic Therapy Beyond First -line Treatment for Advanced Cervical Cancer. Clin 
Oncol (R.Coll.Radiol.), 29, 153 -160. 
Miller, D. S., Blessing, J. A., Bodurka, D. C., Bonebrake, A. J., & Schorge, J. O. (2008). Evaluation 
of pemetrexed (Alimta, LY23151 4) as second line chemotherapy in persistent or recurrent 
carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol.Oncol, 
110, 65 -70. 
Monk, B. J., Sill, M. W., Burger, R. A., Gray, H. J., Buekers, T. E., & Roman, L. D. (2009). P hase II 
trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the 
cervix: a gynecologic oncology group study. Journal of Clinical Oncology, 27, 1069 -1074.  
Muggia, F. M., Blessing, J. A., Method, M., Miller, D. S., John son, G. A., Lee, R. B. et al. (2004). 
Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a 
Gynecologic Oncology Group study. Gynecol.Oncol, 92, 639 -643. 
Rose, P. G., Blessing, J. A., Lele, S., & Abulafia, O. (2006).  Evaluation of pegylated liposomal 
doxorubicin (Doxil) as second -line chemotherapy of squamous cell carcinoma of the cervix: a 
phase II study of the Gynecologic Oncology Group. Gynecol.Oncol, 102, 210 -213. 
Santin, A. D., Sill, M. W., McMeekin, D. S., Leita o, M. M., Jr., Brown, J., Sutton, G. P. et al. (2011). 
Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non -
squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol.Oncol, 
122, 495 -500. 
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  85 Schellens , J. H. M., Marabelle, A., Zeigenfuss, S., Ding, J., Pruitt, S. K., & Chung, H. C. (2017). 
Pembrolizumab for previously treated advanced cervical squamous cell cancer: Preliminary 
results from the phase 2 KEYNOTE -158 study. Journal of Clinical Oncology, 35 , 5514.  
Schilder, R. J., Blessing, J., & Cohn, D. E. (2005). Evaluation of gemcitabine in previously treated 
patients with non -squamous cell carcinoma of the cervix: a phase II study of the Gynecologic 
Oncology Group. Gynecol.Oncol, 96, 103 -107. 
Sun, M. M. , Beam, K. S., Cerveny, C. G., Hamblett, K. J., Blackmore, R. S., Torgov, M. Y. et al. 
(2005). Reduction -alkylation strategies for the modification of specific monoclonal antibody 
disulfides. Bioconjugate Chemistry (Washington, DC), 16, 1282 -1290.  
Tewari, K. S., Sill, M. W., Long, H. J., III, Penson, R. T., Huang, H., Ramondetta, L. M. et al. (2014). 
Improved survival with bevacizumab in advanced cervical cancer. N.Engl.J.Med., 370, 734 -
743. 
The World Medical Association (2013). Declaration of Helsinki. 64t h WMA General Assembly, 
Fortaleza, Brazil.  
Torfs, S., Cadron, I., Amant, F., Leunen, K., Berteloot, P., & Vergote, I. (2012). Evaluation of 
paclitaxel/carboplatin in a dose dense or weekly regimen in 66 patients with recurrent or 
primary metastatic cervical cancer. Eur.J Cancer, 48, 1332 -1340.  
UK MHRA. (2014). Recommendations related to contraception and pregnancy testing in clinical 
trials. Advisory non -binding guidance supported by national competent authorities represented 
at the CTFG -meeting in Rome 2014 -09-15. 
 
 
  
Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  86 Appendix 1  Recommendations Related to Contraception and Pregnancy Testing in Clinical 
Trials  
 
 
 
 
 

Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  87  

Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  88  

Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  89  

Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  90  

Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  91  

Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  92  

Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  93  

Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  94  

Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  95  

Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  96  

Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  97  

Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  98  
  

Document Name: GCT1015 -04 Protocol  Genmab  
Document Number: TMF -03351   ENGOT -cx6 
Version: 7.0 GOG -3023  
Confidential  99 Appendix 2  INVESTIGATOR AGREEMENT  
 
 
1. I have carefully read this protocol entitled “ A Single arm, Multicenter, International Trial of 
Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic 
Cervical Cancer ” and agree that it contains all the necessary information required to conduct 
the trial. I agree to conduct this trial as  outlined in the protocol . 
2. I understan d that this trial will not be initiated without approval of the appropriate 
Institutional Review Committee/Independent Ethics Committee (IRB/IEC), and that all 
administrative requirements of the  governing body of the Institution will be complied with 
fully . 
3. Informed written consent will be obtained from all participating patients in accordance with 
institutional guidelines, FDA requirements as specified in Title 21 CFR, Part 50, the 
European Union Directive 2001/20/EC  and its associated Detailed Guidances, European 
Union GCP Directive 2005/28/EC  (replaced by 536/2014), the Declaration of Helsinki  and 
in the guideline on good clinical practice . 
4. I will enroll patients who meet the protocol criteria for entry.  
5. I understand that my signature on each completed el ectronic Case Report Form (eCRF) 
indicates that I  have carefully reviewed the complete set of eCRFs and accept full 
responsibility for the contents thereof.   
6. I understand that the information presented in this trial protocol is confidential, and I hereby 
assure that no information based on the conduct of the trial will be released without prior 
consent from the Sponsor unless this requirement is superseded by the Food and Drug 
Administration, a Competent Authority of the  European Union or another Regulatory  
Authority.  
 
 
 
 
 
Investigator:  
 
 
 
 
Name: ____________________________   Site : ___ ________________________  
 
 
 
 
Signature : __________________________   Date: ____________________________  
 
  